Imatinib cuts mast cells, reduces airway response

BY MARY ANN MOON
Frontline Medical News

Imatinib decreased airway mast-cell counts and airway hyperresponsiveness in adults with asthma, who were not responding well to maximal therapy, according to a report published online May 17 in the New England Journal of Medicine.

Imatinib is an inhibitor of the stem-cell factor receptor KIT, which is essential for mast-cell development and survival in bodily tissues. This study’s findings suggest that KIT-dependent processes and mast cells contribute to the pathobiology of severe asthma.

“These data are not clinically directive, but they set the stage for follow-up studies targeting mast cells,” said Katherine N. Cahill, MD, of Brigham and Women’s Hospital and Harvard Medical School, both in Boston, and her associates.

The researchers undertook this study because imatinib is known to reduce bone marrow mast cells and tryptase levels in chronic myeloid leukemia and to reduce serum tryptase in patients with pulmonary hypertension. Tryptase is a marker of mast-cell burden and activation when detected in extracellular fluids.

COMING SOON
A new look for CHEST Physician
HELP PRESERVE MORE LUNG FUNCTION
Reduce lung function decline with Esbriet®1–4

Indication
Esbriet® (pirfenidone) is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).1

Select Important Safety Information
Elevated liver enzymes: Increases in ALT and AST >3× ULN have been reported in patients treated with Esbriet. In some cases these have been associated with concomitant elevations in bilirubin. Patients treated with Esbriet had a higher incidence of elevations in ALT or AST than placebo patients (3.7% vs 0.8%, respectively). No cases of liver transplant or death due to liver failure that were related to Esbriet have been reported. However, the combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury that could lead to death or the need for liver transplants in some patients. Conduct liver function tests (ALT, AST, and bilirubin) prior to initiating Esbriet, then monthly for the first 6 months and every 3 months thereafter. Dosage modifications or interruption may be necessary.

Photosensitivity reaction or rash: Patients treated with Esbriet had a higher incidence of photosensitivity reactions (9%) compared with patients treated with placebo (1%). Patients should avoid or minimize exposure to sunlight (including sunlamps), use a sunblock (SPF 50 or higher), and wear clothing that protects against sun exposure. Patients should avoid concomitant medications that cause photosensitivity. Dosage reduction or discontinuation may be necessary.

Gastrointestinal disorders: Gastrointestinal events of nausea, diarrhea, dyspepsia, vomiting, gastroesophageal reflux disease, and abdominal pain were more frequently reported in patients treated with Esbriet. Dosage reduction or interruption for gastrointestinal events was required in 18.5% of patients in the 2403 mg/day group, as compared to 5.8% of patients in the placebo group; 2.2% of patients in the Esbriet 2403 mg/day group discontinued treatment due to a gastrointestinal event, as compared to 1.0% in the placebo group. The most common (>2%) gastrointestinal events that led to dosage reduction or interruption were nausea, diarrhea, vomiting, and dyspepsia. Dosage modifications may be necessary in some cases.

BROAD PATIENT POPULATION

DEMONSTRATED EFFICACY

Clinical trials included patients with IPF with a range of clinical characteristics, demographics, and select comorbidities*†‡

In clinical trials, Esbriet preserved more lung function by delaying disease progression for patients with IPF1–4

IPF=idiopathic pulmonary fibrosis.
*Baseline characteristics (including clinical characteristics, demographics, and select comorbidities) were well balanced across treatment groups, with 1247 patients randomized to receive Esbriet (n=623) or placebo (n=624).1,2
†The safety and efficacy of Esbriet were evaluated in three phase 3, randomized, double-blind, placebo-controlled, multicenter trials in which 1247 patients were randomized to receive Esbriet (n=623) or placebo (n=624).2 In ASCEND, 555 patients with IPF were randomized to receive Esbriet 2403 mg/day or placebo for 52 weeks. Eligible patients had percent predicted forced vital capacity (%FVC) between 50%–90% and percent predicted diffusing capacity of lung for carbon monoxide (%DLCO) between 30%–90%. The primary endpoint was change in %FVC from baseline at 52 weeks.3 In CAPACITY 004, 348 patients with IPF were randomized to receive Esbriet 2403 mg/day or placebo. Eligible patients had %FVC ≥50% and %DLCO ≥35%. In CAPACITY 006, 344 patients with IPF were randomized to receive Esbriet 2403 mg/day or placebo. Eligible patients had %FVC ≥50% and %DLCO ≥35%. For both CAPACITY trials, the primary endpoint was change in %FVC from baseline at 72 weeks.1 Esbriet had a significant impact on lung function decline and delayed progression of IPF vs placebo in ASCEND.2,3 Esbriet demonstrated a significant effect on lung function for up to 72 weeks in CAPACITY 004, as measured by %FVC and mean change in FVC (mL).4 No statistically significant difference vs placebo in change in %FVC or decline in FVC volume from baseline to 72 weeks was observed in CAPACITY 006.2,4
‡In clinical trials, serious adverse reactions, including elevated liver enzymes, photosensitivity reactions, and gastrointestinal disorders, have been reported with Esbriet. Some adverse reactions with Esbriet occurred early and/or decreased over time (ie, photosensitivity reactions and gastrointestinal events).2
†Esbriet Access Solutions offers a range of access and reimbursement support for your patients and practice. Clinical Coordinators are available to educate patients with IPF. The Esbriet® Inspiration Program™ motivates patients to stay on treatment.
*The safety of pirfenidone has been evaluated in more than 1400 subjects, with over 170 subjects exposed to pirfenidone for more than 5 years in clinical trials.2

Genentech
A Member of the Roche Group
© 2017 Genentech USA, Inc. All rights reserved. ESB/021215/0039(T)ad(2) 04/17
Smoking causes decreased exposure to Esbriet, which may alter the efficacy profile of Esbriet. Instruct patients to stop smoking prior to treatment with Esbriet and to avoid smoking when using Esbriet.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see Brief Summary of Prescribing Information on adjacent pages for additional Important Safety Information.


Adverse reactions: The most common adverse reactions (≥10%) are nausea, rash, abdominal pain, upper respiratory tract infection, diarrhea, fatigue, headache, dyspepsia, dizziness, vomiting, anorexia, gastroesophageal reflux disease, sinusitis, insomnia, weight decreased, and arthralgia.

Drug interactions: Concomitant administration with strong inhibitors of CYP1A2 (eg, fluvoxamine) significantly increases systemic exposure of Esbriet and is not recommended. Discontinue prior to administration of Esbriet. If strong CYP1A2 inhibitors cannot be avoided, dosage reductions of Esbriet are recommended. Monitor for adverse reactions and consider discontinuation of Esbriet as needed.

Concomitant administration of Esbriet and ciprofloxacin (a moderate inhibitor of CYP1A2) moderately increases exposure to Esbriet. If ciprofloxacin at the dosage of 750 mg twice daily cannot be avoided, dosage reductions are recommended. Monitor patients closely when ciprofloxacin is used.

Agents that are moderate or strong inhibitors of both CYP1A2 and CYP isoenzymes involved in the metabolism of Esbriet should be avoided during treatment. The concomitant use of a CYP1A2 inducer may decrease the exposure of Esbriet, and may lead to loss of efficacy. Concomitant use of strong CYP1A2 inducers should be avoided.

Specific populations: Esbriet should be used with caution in patients with mild to moderate (Child Pugh Class A and B) hepatic impairment. Monitor for adverse reactions and consider dosage modification or discontinuation of Esbriet as needed.

The safety, efficacy, and pharmacokinetics of Esbriet have not been studied in patients with severe hepatic impairment. Esbriet is not recommended for use in patients with severe (Child Pugh Class C) hepatic impairment.

Esbriet should be used with caution in patients with mild (CLcr 50–80 mL/min), moderate (CLcr 30–50 mL/min), or severe (CLcr less than 30 mL/min) renal impairment. Monitor for adverse reactions and consider dosage modification or discontinuation of Esbriet as needed. The safety, efficacy, and pharmacokinetics of Esbriet have not been studied in patients with end-stage renal disease requiring dialysis. Use of Esbriet in patients with end-stage renal diseases requiring dialysis is not recommended.

Learn more about Esbriet and how to access medication at EsbrietHCP.com
Some ceased glucocorticoid use

“Frequent or long-term use of systemic corticosteroids can lead to potentially life-threatening complications, including osteoporosis, diabetes, cardiovascular disease, and adrenal suppression,” Parameswaran Nair, MD, PhD, professor of medicine at McMaster University, Hamilton, Ont., said in a press release. “We need new, safe therapies that would replace the need for systemic corticosteroids for patients with severe asthma.”

To test benralizumab’s effectiveness, the investigators measured a baseline level of glucocorticoid dosage of 220 patients with severe, uncontrolled asthma. Patients were then given one of three treatment options: one dose of benralizumab every 4 weeks, one dose of benralizumab every 8 weeks, or a placebo.

All three treatments were decreased each time until minimal dosage was found while still maintaining asthma control.

“The average age of patients was approximately 50 years; the majority of

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>% of Patients (0 to 118 Weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>ESBRIET 2403 mg/day (N = 623)</td>
</tr>
<tr>
<td></td>
<td>36%</td>
</tr>
<tr>
<td>Rash</td>
<td>30%</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>24%</td>
</tr>
<tr>
<td>Upper Respiratory Tract Infection</td>
<td>27%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>26%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>26%</td>
</tr>
<tr>
<td>Headache</td>
<td>22%</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>19%</td>
</tr>
<tr>
<td>Diabesness</td>
<td>18%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>13%</td>
</tr>
<tr>
<td>Anorexia</td>
<td>13%</td>
</tr>
<tr>
<td>Gastro-esophageal Reflux Disease</td>
<td>11%</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>11%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>10%</td>
</tr>
<tr>
<td>Weight Decreased</td>
<td>10%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>10%</td>
</tr>
</tbody>
</table>

Adverse reactions occurring in ≥5 to <10% of ESBRIET-treated patients and more commonly than placebo are photosensitivity reaction (9% vs. 1%), decreased appetite (8% vs. 3%), pruritus (8% vs. 5%), asthma (8% vs. 4%), dysgeusia (8% vs. 2%), and non-cardiac chest pain (5% vs. 4%).

6.2 Postmarketing Experience

In addition to adverse reactions identified from clinical trials the following adverse reactions have been identified during post-approval use of pirfenidone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.

7 DRUG INTERACTIONS

7.1 CYP1A2 Inhibitors

Pirfenidone is metabolized primarily (70 to 80%) via CYP1A2 with minor contributions from CYP3A4 enzymes including CYP3A4, 2C19, 2D6 and 2E1. Strong CYP1A2 inhibitors

The concomitant administration of ESBRIET and fluvoxamine or other strong CYP1A2 inhibitors (e.g., enoxacin) is not recommended because it significantly increases exposure to ESBRIET (see Clinical Pharmacology section 12.3 in full Prescribing Information). Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during
patients in both groups of patients receiving benralizumab, 24 patients (33%) in the 4-week group and 27 patients (37%) in the 8-week group showed a 90% reduction from their baseline glucocorticoid dosage. In contrast, only nine patients (12%) in the placebo group experienced a 90% drop in glucocorticoid use.

The researchers also found benralizumab might be useful in a subgroup of patients with a baseline prednisone dose of less than 12.5 mg. These patients were more likely to stop taking their glucocorticoid dose if they were taking benralizumab instead of the placebo. Specifically, patients who took benralizumab every 4 weeks were 5.23 times more likely, and those who took the biologic every 8 weeks were 4.19 times more likely, to cease using glucocorticoids.

Similar to the current biologics used to treat severe eosinophilic asthma, mepolizumab and reslizumab, benralizumab is a form of a monoclonal antibody. Instead of targeting interleukin-5, benralizumab works against a subunit of the interleukin-5 receptor. The investigators said this aspect of benralizumab may explain why it was successful in this study.

“Targeting of the alpha subunit of the interleukin-5 receptor with benralizumab has potential advantages over existing anti–interleukin-5 therapies,” Dr. Nair said. “By targeting the interleukin receptor rather than the cytokine, luminal depletion of eosinophils can occur, which may be related to greater clinical efficiency.”

The investigators noted that forced expiratory volume in 1 second levels seemingly unaffected by benralizumab. This study was limited by the length of the trials, which lasted 28 weeks. Investigators also noted that 20% of the original patients were not used in the final population. This study was sponsored by, and organized in partnership with, AstazaZeneca. All of the investigators reported receiving personal fees, grants, or other support from AstraZeneca, or being under contract with the company. Most of the authors also reported relationships with other pharmaceutical companies.

ezimmerman@fronlinemed.com
On Twitter @ezatweets

Dr. Parameswaran Nair speaks during a session at the ATS.
Mepolizumab boosts remission in EGPA

**Eosinophilic granulomatosis with polyangiitis went into remission for 24 weeks in 28% of those treated.**

BY MARY ANN MOON
Frontline Medical News

A dding mepolizumab to standard-of-care glucocorticoids with or without immunosuppressors can induce remission in many patients who have eosinophilic granulomatosis with polyangiitis (EGPA), according to a report published online May 18 in the New England Journal of Medicine.

EGPA, a rare disorder characterized by asthma, sinusitis, pulmonary infiltrates, neuropathy, and eosinophilic vasculitis in at least one end-organ, frequently relapses despite glucocorticoid therapy or fails to respond adequately to the treatment. Patients have elevated levels of the cytokine interleukin-5, which regulates eosinophil maturation, differentiation, and proliferation. Neutralizing this cytokine is thought to be a potential therapeutic approach, said Michael E. Wechsler, MD, of National Jewish Health, Denver, and his associates.

Proof-of-concept studies have demonstrated the efficacy of subcutaneous mepolizumab, an anti-interleukin-5 monoclonal antibody, in EGPA, so Dr. Wechsler and his colleagues assessed the safety and efficacy of a 1-year course of mepolizumab (300 mg) as add-on therapy in a double-blind, randomized, phase III trial, which involved 136 adults treated at 31 academic medical centers in nine countries. The study was sponsored by GlaxoSmithKline and the National Institute of Allergy and Infectious Diseases.

The first of two primary efficacy endpoints was the total accrued weeks of remission. A total of 28% of the mepolizumab group achieved remission for at least 24 weeks, compared with only 3% of the placebo group, for an odds ratio of 5.91.

The second primary efficacy endpoint was the proportion of patients in remission at both week 36 and week 48. Again, significantly more patients in the mepolizumab group (32%) than in the placebo group (3%) met this endpoint (OR, 16.74).

Mepolizumab also proved superior to placebo regarding numerous secondary endpoints, the investigators said (N Engl J Med. 2017 May 18. doi: 10.1056/NEJMoa1702079). More patients who received active treatment achieved remission within the first 6 months of treatment and remained in remission for a full year (19% vs. 1%; OR, 19.65). The time to first relapse was significantly longer for mepolizumab, with only 56% of that group experiencing a relapse within 1 year, compared with 82% of the placebo group. The annualized relapse rate was half as high with mepolizumab (1.14) as with placebo (2.27).

In addition, patients in the mepolizumab group were more likely to reduce their doses of glucocorticoids (OR, 0.20) or discontinue the drugs altogether (18% vs. 3% taking placebo).

Mepolizumab was most effective among the 79 patients who had a high absolute eosinophil count (150 or more cells per cubic millimeter) at baseline. In this subgroup, 33% of patients taking mepolizumab achieved remission for 6 months or more, compared with none of the patients taking placebo (OR, 26.1).

Although the effectiveness of mepolizumab in this difficult-to-treat population was noteworthy, only about half of the patients given the active treatment achieved remission as defined by the study protocol. It is unclear why the drug was not effective in...
completed the trial.

Fifty patients, 24 in the imatinib group and 26 in the placebo group, were assigned to 24 weeks of either oral mepolizumab or matching placebo (30 participants) or a placebo group is consistent with the placebo group. The small improvement in the placebo group is consistent with a delayed improvement in airway hyperresponsiveness for several months after they started inhaled high-dose, anti-inflammatory glucocorticoid therapy. The near–50-mL difference in the change in baseline FEV₁ between the imatinib and placebo groups is small, but it is likely to be important in light of the population we studied,” Dr. Cahill and her associates wrote.

In addition, exploratory analyses showed that the reduction in airway hyperresponsiveness with imatinib “negatively correlated with baseline blood eosinophil counts, and baseline numbers of neutrophils in bronchoalveolar lavage fluid were strongly correlated with increases in FEV₁. Together, these findings support a role for mast cells in noneosinophilic asthma. Since almost half of the patients with severe asthma have neutrophilic airway inflammation, we speculate that KIT inhibition might represent an important approach to treatment for this group,” they said.

This study was supported by the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, the Vink family, and the Kaye family; Novartis provided imatinib free of charge.

The authors’ financial disclosures are available at www.nejm.org.

Serum tryptase down by 43%

Imatinib from page 1

and it is elevated in the bronchoalveolar lavage fluid from patients with uncontrolled asthma.

To examine whether imatinib would decrease mast-cell counts and activation in the airways of adults with severe, refractory asthma, the investigators performed the randomized, double-blind proof-of-principle trial at seven academic centers across the United States over the course of 5 years.

A total of 62 patients were assigned to 24 weeks of either oral imatinib (32 participants) or a matching placebo (30 participants). Fifty patients, 24 in the imatinib group and 26 in the placebo group, completed the trial.

The primary outcome measure was the change in airway hyperresponsiveness at 6 months, as measured by the increase in the concentration of methacholine that causes significant bronchoconstriction (PC₂₀).

Imatinib decreased airway hyperresponsiveness to a greater degree than did placebo. Imatinib increased PC₂₀ by a mean of 1.20 doubling doses at 3 months and by a mean of 1.73 doubling doses at 6 months, compared with 0.03 and 1.07, respectively, for placebo.

The small improvement in the placebo group is consistent with a phenomenon reported in other studies, in which patients show a delayed improvement in airway hyperresponsiveness for several months after they started inhaled glucocorticoids, Dr. Cahill and her associates noted (N Engl J Med. 2017 May 18. doi: 10.1056/NEJ-Moa1613125).

Imatinib also reduced mast-cell activity as measured by serum and airway levels of tryptase. Serum tryptase decreased by 43% in the imatinib group, compared with a 12% decline in the placebo group. And tryptase levels in bronchoalveolar lavage fluid tended to decrease in the imatinib group but to increase in the placebo group.

Imatinib also increased mean forced expiratory volume in 1 second (FEV₁).

‘Although the increase in FEV₁ may not seem substantial, it suggests that mast-cell–dependent processes contribute to airway obstruction in these patients despite high-dose, anti-inflammatory glucocorticoid therapy. The near–50-mL difference in the change in baseline FEV₁ between the imatinib and placebo groups is small, but it is likely to be important in light of the population we studied,” Dr. Cahill and her associates wrote.

In addition, exploratory analyses showed that the reduction in airway hyperresponsiveness with imatinib “negatively correlated with baseline blood eosinophil counts, and baseline numbers of neutrophils in bronchoalveolar lavage fluid were strongly correlated with increases in FEV₁. Together, these findings support a role for mast cells in noneosinophilic asthma. Since almost half of the patients with severe asthma have neutrophilic airway inflammation, we speculate that KIT inhibition might represent an important approach to treatment for this group,” they said.

This study was supported by the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, the Vink family, and the Kaye family; Novartis provided imatinib free of charge.

The authors’ financial disclosures are available at www.nejm.org.

Directions for future research

The study by Michael E. Wechsler, MD, and his associates can be considered proof of concept. Now, researchers must turn to identifying biomarkers that predict the success or failure of mepolizumab in patients.

Researchers must also elucidate the fate of eosinophils in the tissues, especially in vasculitic lesions, after treatment with mepolizumab. And they should address possible synergistic activity when the drug is given together with immunosuppressants such as azathioprine and cyclophosphamide.

In addition, future studies should include patients who have organ-threatening or life-threatening eosinophilic granulomatosis with polyangiitis, who were excluded from this trial but who are most in need of novel treatments.

Ratko Djukanovic, MD, is with the University of Southampton (England) and the National Institute for Health Research Southampton Biomedical Research Centre. Paul M. O’Byrne, MD, is with the Firestone Institute for Respiratory Health within St. Joseph’s Healthcare and McMaster University in Hamilton, Ont. Dr. Djukanovic and Dr. O’Byrne both reported financial relationships with pharmaceutical companies outside their editorial. They made these remarks in an editorial accompanying Dr. Wechsler and colleagues’ report (NEJM. 2017 May 18. doi: 10.1056/NEJ-Mc1704402).

VIEW ON THE NEWS

Vera A. De Palo, MD, MBA, FCCP, comments: This study presents important findings that continue to deepen our understanding of the key factors in the different phenotypes of asthma. The authors point out that this sets the stage for further research in the exploration of targeted therapies that could help some of our sickest and most difficult-to-treat asthmatic patients.

Learn More

CHEST Annual Meeting is your connection to education opportunities that will help optimize your patient care. Hundreds of clinically relevant sessions and the community of innovative problem-solvers who attend will inspire and energize you and your career.

Learn More

chestmeeting.chestnet.org
Invasive mediastinal staging for high-risk NSCLC

By Mark S. Lesney

Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) appears to be cost effective for use in non–small cell lung cancer (NSCLC) staging if the prevalence of mediastinal lymph node metastasis (MLNM) is greater than or equal to 2.5%, according to the results of single institution modeling study. In addition, the study found that confirmatory mediastinoscopy should be performed in high-risk patients in cases of negative EBUS-TBNA.

Katarzyna Czarnecka-Kujawa, MD, of the University of Toronto and Toronto General Hospital, and her colleagues performed a decision analysis to compare health outcomes and costs of four mediastinal staging strategies. They assessed the following: no invasive staging, endobronchial ultrasound-guided transbronchial needle aspiration, mediastinoscopy, and EBUS-TBNA followed by mediastinoscopy if EBUS-TBNA results were negative. They determined incremental cost-effectiveness ratios (ICER) for all strategies and performed comprehensive sensitivity analyses using a willingness to pay threshold of $80,000 (Canadian)/quality-adjusted life-year (QALY).

They used data obtained for...

After exclusions, they utilized a final case count of 499 cases for developing their surgical and procedure cost analysis, and a total of 750 cases in their endoscopy database for endoscopy analysis. For the base-case analysis, they assumed a prevalence of mediastinal metastasis of 9%, and obtained the prevalence of a pathologic lymph nodal stage disease following EBUS-TBNA from their institutional data.

Their results showed that EBUS-TBNA followed by mediastinoscopy was the strategy that resulted in the highest QALYs, but that it had a prohibitive ICER of greater than $1.4 million/QALY. Accordingly, it may not be justifiable to use mediastinoscopy after negative EBUS-TBNA in all patients, the researchers noted. However, the researchers stated that "[the] benefit conveyed Continued on following page
by detecting mediastinal metastatic disease becomes more apparent as the prevalence of MLNM increases, with confirmatory mediastinoscopy becoming cost effective in cases of negative EBUS-TBNA in patients with moderate to high probability of MLNM (greater than 57%). Our model points out that there is a well-defined role for the use of different modalities, including mediastinoscopy. This stresses the need for ongoing focus on maintenance of competence and skill acquisition in mediastinoscopy and EBUS-TBNA by currently practicing and future thoracic surgeons respectively,” the researchers concluded.

Dr. Czarnecka-Kujawa disclosed that she is a research consultant with Olympus America. The study was funded in part by agencies of the Austrian government.

mlesney@frontlinemedcom.com

---

**Endobronchial US appears to remain the method for all seasons**

The authors make a compelling argument for invasive mediastinal staging in patients with clinical stage I non–small cell lung cancer and acknowledge that this conflicts with current guidelines, according to Biniam Kidane, MD, of the University of Manitoba, Winnipeg, in his invited comments on the study in the Journal of Thoracic and Cardiovascular Surgery (2017 Mar 10; doi:10.1016/j.jtcvs.2017.02.051).

Their single-payer system is likely to have a different willingness-to-pay threshold, compared with those in other countries, especially the United States, where the EBUS-TBNA strategy without invasive staging is likely to remain costly.

Dr. Kidane applauded the authors on their methodologically rigorous analysis with robust sensitivity analyses to capture a wide range of mediastinal lymph node metastasis (MLNM) prevalence and EBUS-TBNA efficiencies and “provide a brilliant pictorial representation of their analyses that allows readers to identify the most cost-effective strategy by finding the intersection of their local MLNM prevalence and EBUS sensitivities.”

"Cost-economic analyses such as these provide a window into the factors necessary to bridge the gap between the reality of the abstract to the realm of local reality. When interpreting these findings, clinicians should consider: (1) What EBUS resources are available? (2) What is your local EBUS sensitivity? (3) What is the prevalence of MLNM?" Dr. Kidane concluded, with the caveat that such studies are not infallible and models are based on assumptions and must be treated with care.

Dr. Kidane reported no disclosures with regard to commercial support.
SYNDROMIC TESTING FROM BIOFIRE:

Improve Patient Outcomes.

BioFire’s syndromic testing allows you to quickly identify infectious agents that produce similar symptoms in patients. BioFire’s innovative PCR technology provides answers in a clinically actionable timeframe using any of the FilmArray® Panels:

- **Respiratory Panel**: Enable a faster, more informed diagnosis that can reduce the usage and duration of antibiotic administration and decrease length of hospital stay.

- **Blood Culture Identification Panel**: Reduce time to effective therapy and antimicrobial de-escalation which may improve patient survival rates.

- **Gastrointestinal Panel**: Quickly ruling in or out enteric pathogens may improve patient care by preventing misdiagnosis and mistreatment.

- **Meningitis/Encephalitis Panel**: Quickly identifying a CNS infection as viral, bacterial or fungal may reduce patient mortality.

To learn how syndromic testing from BioFire can help YOU improve patient outcomes, visit [biofiredx.com](http://biofiredx.com)

Data on file at BioFire Diagnostics.

**Syndromic Testing: The Right Test, The First Time.**

*Respiratory • Blood Culture Identification • Gastrointestinal • Meningitis/Encephalitis*
Sleep disorder diagnoses less common in women

**BY ELI ZIMMERMAN**

Frontline Medical News

Women are less likely to be diagnosed with and treated for sleep-disordered breathing, despite having symptoms similar to those of men, a Swedish study showed.

In a survey of 10,854 subjects, 14% of women reported being diagnosed with obstructive sleep apnea (OSA), compared with 25% of men (P < 0.001), and 9% of women reported having any OSA treatment, compared with 16% of men (Sleep Med. 2017. doi: 10.1016/j.sleep.2017.02.032).

Underdiagnosis of sleep-disordered breathing (SDB) in women may have dire consequences, as symptoms, specifically snoring and excessive daytime sleepiness (EDS), correlate with increased risk for hypertension and diabetes, regardless of gender, according to Eva Lindberg, PhD, professor in the department of medical sciences, respiratory, allergy, and sleep research at Uppsala (Sweden) University, and her colleagues.

The mean age of the patients at baseline was 41 years. Mean body mass index was 25.4 kg/m² for men and 24 kg/m² for women.

On initial testing, approximately three times the percentage of men reported having issues with snoring and no EDS, compared with women (19% vs. 6% respectively), while more women reported the opposite, EDS but no snoring (19% vs. 11%). A slightly larger percentage of men reported having both symptoms (7.3% vs. 4.5%).

Investigators hypothesized the disparity between women and men reporting problems with snoring may be caused by gender expectations.

“It is more probable that SDB is still assumed to be a condition associated predominantly with men, and women feel ashamed of reporting these symptoms and seeking medical advice,” said Dr. Lindberg and her co-investigators. These gender expectations may “contribute to females being less inclined to seek medical advice due to SDB symptoms.”

In a follow-up survey conducted 11 years after the initial one, doctors found 1,716 and 319 patients had received a new diagnosis for hypertension and diabetes, respectively.

While incidence was greater in men than in women for both (hypertension: 18.6% vs. 15.8% [P < 0.001] and 3.6 vs. 2.4% [P < 0.001], respectively), the investigators found “after adjusting for BMI and snoring at baseline, none of these gender differences remained significant.”

Physicians’ perception of SDB is partially responsible for the number of women who go undiagnosed, according to the researchers. Because SDB is considered to occur predominantly in males, doctors may overlook symptoms in female patients that would otherwise be a cause for further testing, they noted.

“[E]ven among health professionals, SDB is still usually attributed to a male population, and female patients are therefore less frequently asked about the cardinal symptoms of snoring and sleepiness and do not therefore undergo sleep recordings. ... Also, among patients with obesity hypoventilation syndrome, females are generally diagnosed when the disease is more advanced and significantly more frequently develop acute disease before achieving treatment,” the investigators wrote.

Dr. Lindberg and her team suggested engaging female patients more frequently about SDB symptoms, as well as referring patients with positive symptoms to participate in a sleep study.

The current study was limited by the nature of the data, which were self-reported. Patients were not surveyed via the Epworth Sleepiness Scale.

The study was funded by grants from the Norwegian Research Council, the Icelandic Research Council, Aarhus University, the Swedish Heart-Lung Foundation, and the Estonian Science Foundation.

The investigators reported no relevant financial disclosures.

**VIEW ON THE NEWS**

Krishna Sundar, MD, FCCP, comments: The authors discuss the important topic of differing expression of OSA in male versus female subjects that may lead to underrecognition of sleep apnea in women.

---

Oxygen desaturation index produces disparate data

**BY ELI ZIMMERMAN**

Frontline Medical News

WASHINGTON – Oxygen desaturation index (ODI) scores showed significant variation across two software systems, a study showed.

The researchers assessed the ODI scores of 106 patients using the ResMed ApneaLink Plus system (AL) and the Compumedics Grael Profusion PSGJ system (Comp). “AL ODI values tended to be higher than Comp ODI values, but with significant variability,” they said.

AL showed a bias of an additional 4.4 events per hour (95% limits of agreement, –5.8 to 14.6 events per hour) for ODI scores at 4% desaturation and a bias of an additional 7.1 events per hour (95% limits of agreement, –6.4 to 20.6 events per hour) at 3% desaturation (J Clin Sleep Med. 2017;13[4]:599-605).

This may be problematic for physicians evaluating patients during sleep studies who rely on ODI scores at 3% and 4% desaturations to create accurate apnea severity assessments, the investigators said.

“The wide limits of agreement in our study highlight that clinicians cannot be confident that an ODI4% recorded in the AL is the same as that recorded in the Comp,” wrote Yvonne Ng, MBBS, of the department of lung and sleep medicine at Monash Health, Victoria, Australia, and her colleagues. “The differences are large enough to significantly affect diagnostic thresholds for OSA [obstructive sleep apnea] and, in particular, moderate-severe OSA.”

The researchers gathered data from patients undergoing sleep analysis at the Monash Medical Centre, who were, on average, 47 years of age, had a body mass index score of 32 kg/m², and had an apnea hypopnea index (AHI) of 23.2.

ODI3% scores analyzed through Comp diagnosed 66 patients with OSA (ODI3% greater than or equal to 5 events per hour), while desaturation events analyzed through the AL system diagnosed 90 patients, a 36% increase over Comp (P = 0.002).

When researchers tested for moderate to severe OSA (ODI3% greater than or equal to 15 events per hour), 32 patients were diagnosed using the Comp system, compared with 59 patients using the AL system.

Disparities in these measurements create uncertainty among clinicians, who rely on ODI measurements for scores that are accurate and can be easily replicated using an algorithm, the researchers said.

“The current work demonstrates that significantly more patients would receive a diagnosis of OSA, or more particularly, moderate-severe OSA, with the AL ODI, compared to the Comp ODI,” Dr. Ng and her colleagues wrote.

When sensitivity scores for Comp and AL were compared, AL ODI3% scores were significantly more sensitive than Comp, with sensitivity scores of 96% vs. 58%.

Using different fingers for measuring desaturation during the test or differences in algorithms used to assess ODI scores were possible sources of the disparities, the researchers noted.

Differences in internal processing between the two systems were the most likely causes of the discrepancies between the data collected using each system, they added.

Because there is no universal standard for ODI measurements, the researchers were unable to determine which system was more accurate.

Several of the researchers reported receiving financial support, research equipment, or consultancy fees from various entities.

**VIEW ON THE NEWS**

Krishna Sundar, MD, FCCP, comments: This article raises significant concerns about the role of different oximeters in contributing to the variation in hypopnea scoring.

---

ezimmerman@frontlinemedcom.com
On Twitter @eaztweets
Patients accepted side effects

Chronic cough from page 1

complete loss of taste.

However, only 6 patients out of 63 who were randomized to this dosage stopped taking their medication.

The finding suggests that the drug was tolerable for most of the patients.

The results also suggested that lower dosages with less potent adverse effects on taste produced significant cough reductions in some patients.

Patients with chronic, refractory cough are often “willing to accept some taste change to reduce their cough count.

Dr. Jaclyn A. Smith

“Patients are willing to put up with the taste side effects,” Dr. Smith said in a video interview.

The study enrolled patients with chronic, refractory cough at U.S. and U.K. centers and randomized 63 to each of three active treatment arms receiving 7.5 mg, 20 mg, or 50 mg b.i.d. of MK-7264 or to placebo for 12 weeks.

The patients averaged 60 years of age and about three-quarters were women.

On average, they had their cough for more than 10 years, and these patients coughed roughly 30 times an hour when awake.

The study’s primary endpoint was reduction in awake cough frequency, and, after 12 weeks on treatment with 50 mg b.i.d., this had fallen an average of 37%, compared with placebo, said Dr. Smith, who is a professor of respiratory medicine at the University of Manchester (England).

The 7.5-mg and 20-mg b.i.d. dosages each led to cough frequency reductions of about 22% over placebo that were not statistically significant. This was likely a result of the unexpectedly strong placebo effect in the study, Dr. Smith said.

Most of the cough effect was evident after the first 4 weeks on treatment.

Dr. Smith noted that she and her associates “most definitely” plan to progress to a phase III trial. “We really lack effective treatments for cough,” she said.

The study was sponsored by Merck, the company that is developing MK-7264.

Dr. Smith is a consultant with Merck and has a licensing agreement with Vitalograph. A video interview with her on this topic is available at mdedge.com/chestphysician.

mdzoler@frontlinemedcom.com
On Twitter @mitchelzoler
Stage IV sarcoidosis differs in blacks and whites

BY MITCHEL L. ZOLER
Frontline Medical News

WASHINGTON – Black patients with advanced-stage sarcoidosis generally have a pattern of fibrotic scar in their lungs that is different from that of whites, a finding with potentially important implications for prognosis and management.

Systematic assessment of 149 American patients diagnosed with sarcoidosis – 264 whites and 85 blacks – showed that black patients had nearly double the prevalence of advanced, end-stage, Scadding stage IV fibrosis in their lungs, with a 19% rate among whites and a 34% rate among blacks, confirming that blacks generally have worse sarcoidosis, Andy Levy, MD, said at an international conference of the American Thoracic Society.

All these sarcoidosis patients par-
This research confirmed that black patients generally have worse sarcoidosis than white patients.

DR. LEVY

Participated in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study, and underwent CT scanning as part of the study’s protocol. The scans showed that 16 of the 29 black patients with stage IV disease (19% of the total group of 85) had a “honeycomb” structure to their fibrotic scar, compared with 10 of the 50 white patients (4% of the total group of 264). Honeycomb scar is associated with more restrictive disease, characterized by reduced total lung capacity and reduced diffusing capacity of the lungs for carbon monoxide, features seen in these black stage IV patients, said Dr. Levy, a pulmonologist at National Jewish Health in Denver.

Bronchovascular distortion, the more common scar pattern seen in the white patients, results in more obstructive symptoms, such as a reduced ratio of forced expiratory volume in 1 second to forced vital capacity, which Dr. Levy reported as

Continued on following page
a characteristic of the white GRADS patients.

Even though the pulmonary fibrosis was end stage in all the black and white stage IV patients examined, “the scar occurs may depend on genetics or environment, and may affect how the disease manifests.”

Laura Korth, MD, a pulmonologist and professor at the University of California, San Francisco, and lead

Even though the pulmonary fibrosis was end stage in all the black and white stage IV patients examined, “where the scar occurs may depend on genetics or environment, and may affect how the disease manifests,” Dr. Levy noted.
The study’s primary goal is to try to identify “genomic signatures” that link with the clinical phenotypes identified through spirometry, bronchoscopy, CT scans, and physical examinations, Dr. Koh explained. The investigators plan to enroll more patients. “The porcine model validates the findings, she said. “This is an early stage, but we have seen some signals we want to follow-up.”

GRADS is funded by the National Heart, Lung, and Blood Institute. Dr. Levy and Dr. Koh had no relevant financial disclosures.

mzoler@frontlinemedcom.com On Twitter @Mitchelzoler
CRT-D helpful in mild HF with high ejection fraction

WASHINGTON—Patients with mild heart failure symptoms, left bundle branch block, and a left ventricular ejection fraction of 31%-44% who received cardiac resynchronization therapy with a built-in defibrillator experienced a significant reduction in all-cause mortality, compared with those randomized to an implantable cardioverter-defibrillator alone during 7 years of follow-up.

These results from a new MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) long-term follow-up substudy suggest that patients with a relatively preserved ejection fraction greater than 30% benefit from a CRT-D (cardiac resynchronization therapy device) and could potentially be considered for this therapy, said Katherine Vermilye, MD, at the annual meeting of the American College of Cardiology.

This represents a broadening beyond the conclusions earlier reached in the landmark MADIT-CRT. In the primary report, MADIT-CRT investigators concluded that CRT-D significantly reduced the risk of heart failure events, compared with an implantable cardioverter defibrillator (ICD) alone during an average follow-up of 2.4 years in patients with mild symptoms of either ischemic or nonischemic cardiomyopathy, a wide QRS duration, an left ventricular ejection fraction (LVEF) of 30% or less, and left bundle branch block, but not in those who didn’t have left bundle branch block (N Engl J Med. 2009 Oct 1;361[14]:1329-38).

In a subsequent publication, the MADIT-CRT investigators reported that, with extension of follow-up to 7 years, CRT-D also provided a significant benefit in terms of all-cause mortality in addition to the reduced rate of heart failure events (N Engl J Med. 2014 May 1;370[18]:1694-701).

However, even though an LVEF of 30% or less was a requirement for participation in MADIT-CRT, it turned out that, when the initial screening echocardiograms were eventually analyzed in a central core laboratory, one-third of study participants actually had a LVEF that was 30% or less. Thus, investigators concluded that CRT-D could potentially be considered for this population.
A transdermal mitral valve replacement pipe dream

BY BRUCE JANCIN
Frontline Medical News

SNOWMASS, COLO. – Percutaneous mitral valve replacement is unlikely to ever catch on in any way remotely approaching that of transcatheter aortic valve replacement for the treatment of aortic stenosis, Blase A. Carabello, MD, predicted at the Annual Cardiovascular Conference at Snowmass.

“We’ve spent $2 billion looking for methods of percutaneous mitral valve replacement, and yet, I have to wonder if that makes any sense,” said Dr. Carabello, professor of medicine and chief of cardiology at East Carolina University in Greenville, N.C.

“If repair is superior to replacement in primary MR (mitral regurgitation), which I think we all agree is true, and you don’t need to get rid of every last molecule of blood going backward across the mitral valve when you’ve got a good left ventricle, then a percutaneous replacement in primary MR would have only the niche of patients who are inoperable and whose leaflets can’t be grabbed by the MitraClip or some new percutaneous device down the road. And, in secondary MR, it doesn’t seem to matter whether you replace or repair the valve, so why not just repair it with a clip?” he argued.

Numerous nonrandomized studies have invariably demonstrated superior survival for surgical repair versus replacement in patients with primary MR.

VIEW ON THE NEWS

Francis J. Podbielski, MD, FCCP, comments: The author provides valuable insight into how the definition of “success” of a procedure can change depending on the approach to the problem. While the gold standard of open mitral valve repair is 1+ regurgitation or less, those promoting percutaneous valve replacement are willing to accept long term 1+ to 2+ regurgitation. New technology and innovation is critical in medicine, provided the results are at least equivalent or superior to the standard techniques.

Continued from previous page

and more likely to be female than the 824 subjects with an LVEF of 30% or less. They also had a shorter QRS duration – an average of 160 ms, versus 165 ms in patients with an LVEF of 30% or lower – and a smaller baseline left ventricular end systolic volume of 151 mL, compared with 196 mL in patients with a lower LVEF.

In a multivariate Cox regression analysis adjusted for potential confounders, CRT-D in patients with a baseline LVEF greater than 30% was associated with a 54% reduction in the risk of all-cause mortality at 7 years of follow-up, compared with receipt of an ICD-only device and with a smaller yet significant 31% reduction in risk in those with an LVEF of 30% or less. Worsening heart failure events were reduced by 64% in patients with a baseline LVEF greater than 30% who received CRT-D, compared with ICD-only, and by 34% in those with a lower baseline LVEF. The reduction in all-cause mortality seen with CRT-D was confined to patients who were high responders to CRT as defined echocardiographically by at least a 35% change in left ventricular end systolic volume 1 year post implantation. They had an 85% reduction in the risk of death during 7 years of follow-up with CRT-D if their baseline LVEF was greater than 30% and a 58% relative risk reduction if their LVEF was 30% or less.

In contrast, CRT-D brought a significantly reduced risk of heart failure events regardless of whether a patient was a low or high responder, although the magnitude of benefit was greater in the high responders. Among patients with a baseline LVEF greater than 30%, CRT-D low responders had a 52% reduction in risk of heart failure events, compared with ICD recipients, while CRT-D high responders had an 81% relative risk reduction. Similarly, in patients with a baseline LVEF of 30% or less, CRT-D low responders had a 48% reduction in heart failure events and high responders had a 79% risk reduction, compared with the ICD-only group.

Because this is a post hoc analysis, these new MADIT-CRT findings require validation in future studies, Dr. Vermilye observed.

MADIT-CRT was supported by Boston Scientific. Dr. Vermilye reported having no financial conflicts.

bjanclin@frontlinemedcom.com
INDICATIONS
ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). ELIQUIS is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial therapy.

IMPORTANT SAFETY INFORMATION
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA
(A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
(B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
• use of indwelling epidural catheters
• concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
• a history of traumatic or repeated epidural or spinal punctures
• a history of spinal deformity or spinal surgery
• optimal timing between the administration of ELIQUIS and neuraxial procedures is not known
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.

CONTRAINDICATIONS
• Active pathological bleeding
• Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)

WARNINGS AND PRECAUTIONS
• Increased Risk of Thrombotic Events after Premature Discontinuation: Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
• Bleeding Risk: ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.
  – Concomitant use of drugs affecting hemostasis increases the risk of bleeding, including aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRI, SNRI, and NSAIDs.
  – Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.
  – There is no established way to reverse the anticoagulant effect of apixaban, which can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). A specific antidote for ELIQUIS is not available.
• Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS.
DVT/PE
Indicated for the treatment of DVT and PE, and to reduce the risk of recurrent DVT and PE following initial therapy.¹

DVT: deep vein thrombosis; PE: pulmonary embolism.

WARNINGS AND PRECAUTIONS (cont’d)
The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours.

Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

• Prosthetic Heart Valves: The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients.

• Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy: Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

ADVERSE REACTIONS
The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding.

TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS
• ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.

DRUG INTERACTIONS
• Strong Dual Inhibitors of CYP3A4 and P-gp: Inhibitors of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) increase exposure to apixaban and increase the risk of bleeding. For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole,itraconazole, ritonavir, or clarithromycin). In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with strong dual inhibitors of CYP3A4 and P-gp.

• Strong Dual Inducers of CYP3A4 and P-gp: Avoid concomitant use of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events.

• Anticoagulants and Antiplatelet Agents: Coadministration of anticoagulant agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.

PREGNANCY CATEGORY B
There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.


Please see Brief Summary of Full Prescribing Information, including Boxed WARNINGS, on adjacent pages.

ELIQUIS® and the ELIQUIS logo are trademarks of Bristol-Myers Squibb Company. © 2017 Bristol-Myers Squibb. All rights reserved. 432US1701443-02-01 05/17
ELIQUIS® (apixaban) tablets, for oral use

15 ONLY

Brief Summary of Prescribing Information. For complete prescribing information consult official package insert.

INDICATIONS AND USAGE

Brief Summary of Prescribing Information. For complete prescribing information consult [see Dosage and Administration], [see Warnings and Precautions], and [see Clinical Studies (14.1) in full Prescribing Information].

Hemodialysis does not appear to have a substantial impact on apixaban exposure, and therefore, dosage adjustment is not recommended. Activated oral charcoal reduces absorption of apixaban, thereby lowering exposure [see Warnings and Precautions] and Administration (2.4) and Clinical Studies (14.1) in full Prescribing Information].

The safety of ELIQUIS was evaluated in 1 Phase II and 3 Phase III studies including 5924 patients exposed to ELIQUIS 2.5 mg twice daily undergoing major orthopedic surgery of who underwent hip or knee replacement surgery.

In the ARISTOTLE trial, fatal bleeding was an adjudicated death with the primary cause of death as intracranial hemorrhage in a patient with active non-intracranial. No data are available to support the use of ELIQUIS in patients with a bleeding risk of less than moderate severity; therefore, the use of ELIQUIS in patients with a bleeding risk of less than moderate severity is not recommended. In patients with a bleeding risk of less than moderate severity, the use of ELIQUIS is not recommended as an alternative to unfractioned heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may require thrombolysis or pulmonary embolectomy.

The risk of these events may be increased by the postoperative use of indwelling epidural catheters, a history of traumatic or repeated epidural or spinal punctures, a history of spinal deformity or spinal surgery, or an epidural/spinal anesthesia or puncture. [see Warnings and Precautions].

The most common reason for treatment discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE, this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in ARINVERO, in 1.5% and 1.3% of patients on ELIQUIS and warfarin, respectively. [see Warnings and Precautions].

• optimal timing between the administration of ELIQUIS and neuraxial procedures

• a history of traumatic or repeated epidural or spinal punctures

• use of indwelling epidural catheters

• a history of spinal deformity or spinal surgery

• low bleeding or where the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, protamine sulfate and vitamin K antagonist, or consideration of vitamin K antagonist in patients with atrial fibrillation who are not candidates for the postoperative use of indwelling epidural catheters, or when the bleeding would be non-critical in location and easily controlled. Bridging therapy with heparin, pr
Table 6: Adverse Reactions Occurring in ≥1% of Patients Treated for DVT and PE in the AMPLIFY-EXT Study

<table>
<thead>
<tr>
<th>Reaction</th>
<th>ELIQUIS (apixaban)</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=5924</td>
<td>N=840</td>
<td>n (%)</td>
</tr>
<tr>
<td>Major</td>
<td>2 (0.3)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>CRNMA</td>
<td>35 (5.4)</td>
<td>34 (4.1)</td>
</tr>
<tr>
<td>Minor</td>
<td>19 (3.3)</td>
<td>18 (2.2)</td>
</tr>
<tr>
<td>All</td>
<td>54 (9.3)</td>
<td>52 (6.2)</td>
</tr>
</tbody>
</table>

* CRNMA = clinically relevant nonmajor bleeding.

Events associated with such a reaction were counted once per subject, but subjects may have contributed events to multiple endpoints.

Adverse reactions occurring in ≥1% of patients in the AMPLIFY study are listed in Table 7.

Table 7: Adverse Reactions Occurring in ≥1% of Patients Undergoing Extended Treatment for DVT and PE in the AMPLIFY-EXT Study

<table>
<thead>
<tr>
<th>Reaction</th>
<th>ELIQUIS (apixaban)</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=511</td>
<td>N=2676</td>
<td>n (%)</td>
</tr>
<tr>
<td>Major</td>
<td>2 (0.4)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>CRNMA</td>
<td>35 (6.8)</td>
<td>34 (6.5)</td>
</tr>
<tr>
<td>Minor</td>
<td>19 (3.7)</td>
<td>17 (3.1)</td>
</tr>
<tr>
<td>All</td>
<td>54 (10.5)</td>
<td>51 (4.8)</td>
</tr>
</tbody>
</table>

* CRNMA = clinically relevant nonmajor bleeding.

Events associated with such a reaction were counted once per subject, but subjects may have contributed events to multiple endpoints.

Adverse reactions occurring in ≥1% of patients in the AMPLIFY study are listed in Table 8.

Table 8: Adverse Reactions Occurring in ≥1% of Patients Undergoing Extended Treatment for DVT and PE in the AMPLIFY-EXT Study

<table>
<thead>
<tr>
<th>Reaction</th>
<th>ELIQUIS (apixaban)</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=511</td>
<td>N=840</td>
<td>n (%)</td>
</tr>
<tr>
<td>Major</td>
<td>2 (0.4)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>CRNMA</td>
<td>35 (6.8)</td>
<td>34 (6.5)</td>
</tr>
<tr>
<td>Minor</td>
<td>19 (3.7)</td>
<td>17 (3.1)</td>
</tr>
<tr>
<td>All</td>
<td>54 (10.5)</td>
<td>51 (4.8)</td>
</tr>
</tbody>
</table>

* CRNMA = clinically relevant nonmajor bleeding.

Events associated with such a reaction were counted once per subject, but subjects may have contributed events to multiple endpoints.

Adverse reactions occurring in ≥1% of patients undergoing hip or knee replacement surgery in the AMPLIFY study are summarized in Table 9.

Table 9: Adverse Reactions Occurring in ≥1% of Patients Undergoing Extended Treatment for DVT and PE in the AMPLIFY-EXT Study

<table>
<thead>
<tr>
<th>Reaction</th>
<th>ELIQUIS (apixaban)</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=511</td>
<td>N=811</td>
<td>n (%)</td>
</tr>
<tr>
<td>Major</td>
<td>2 (0.4)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>CRNMA</td>
<td>35 (6.8)</td>
<td>34 (6.5)</td>
</tr>
<tr>
<td>Minor</td>
<td>19 (3.7)</td>
<td>17 (3.1)</td>
</tr>
<tr>
<td>All</td>
<td>54 (10.5)</td>
<td>51 (4.8)</td>
</tr>
</tbody>
</table>

* CRNMA = clinically relevant nonmajor bleeding.

Events associated with such a reaction were counted once per subject, but subjects may have contributed events to multiple endpoints.

Adverse reactions occurring in ≥1% of patients undergoing hip or knee replacement surgery in the AMPLIFY-EXT study are listed in Table 10.

Table 10: Adverse Reactions Occurring in ≥1% of Patients Undergoing Extended Treatment for DVT and PE in the AMPLIFY-EXT Study

<table>
<thead>
<tr>
<th>Reaction</th>
<th>ELIQUIS (apixaban)</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=511</td>
<td>N=811</td>
<td>n (%)</td>
</tr>
<tr>
<td>Major</td>
<td>2 (0.4)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>CRNMA</td>
<td>35 (6.8)</td>
<td>34 (6.5)</td>
</tr>
<tr>
<td>Minor</td>
<td>19 (3.7)</td>
<td>17 (3.1)</td>
</tr>
<tr>
<td>All</td>
<td>54 (10.5)</td>
<td>51 (4.8)</td>
</tr>
</tbody>
</table>

* CRNMA = clinically relevant nonmajor bleeding.

Events associated with such a reaction were counted once per subject, but subjects may have contributed events to multiple endpoints.
It is an incredible honor to be recently confirmed as the EVP/CEO for the CHEST organization. As a 23-year veteran of CHEST, I have had the privilege of working with and for many of our leaders, volunteers, and members. Being only the fifth person to lead the organization in an executive leadership role is both humbling and invigorating. CHEST is a dynamic and innovative organization, with a mission to “champion the prevention, diagnosis, and treatment of chest diseases through education, communication, and research.” That mission resonates deeply with me on a personal level, because my mother had COPD. Toward the end of her life, I saw firsthand how it impacted her quality of life and her ability to be a mother and grandmother, and I also saw the important role her pulmonologist and respiratory healthcare providers played in managing her disease. Working for CHEST reminds me every day of the importance of what we do as an organization in order to support what you do as a physician or advanced practice provider.

I am both fortunate and grateful to have such a phenomenal professional staff to work with here at CHEST and to have the outstanding leadership of our Presidents, Past Presidents, Boards, Committees, and NetWorks – all of which have been tremendously supportive during the past 9 months as I filled the Interim EVP role. I am also deeply grateful to those of you who choose to be members and Fellows of CHEST and to be engaged as volunteer leadership, faculty, content experts, authors, and more.

I am both fortunate and grateful to have such a phenomenal professional staff to work with here at CHEST and to have the outstanding leadership of our Presidents, Past Presidents, Boards, Committees, and NetWorks – all of which have been tremendously supportive during the past 9 months as I filled the Interim EVP role. I am also deeply grateful to those of you who choose to be members and Fellows of CHEST and to be engaged as volunteer leadership, faculty, content experts, authors, and more.

I am both fortunate and grateful to have such a phenomenal professional staff to work with here at CHEST and to have the outstanding leadership of our Presidents, Past Presidents, Boards, Committees, and NetWorks – all of which have been tremendously supportive during the past 9 months as I filled the Interim EVP role. I am also deeply grateful to those of you who choose to be members and Fellows of CHEST and to be engaged as volunteer leadership, faculty, content experts, authors, and more.
Building bridges: CHEST Foundation collaborations

Partnering with like-minded advocates and organizations strengthens our collective voice to improve patient outcomes. We choose to partner with others who share our values in creating sustainable, long-lasting change by engaging clinicians, patients, caregivers, and the public on the importance of understanding lung health.

Pulmonary Fibrosis Foundation

We recently collaborated with the Pulmonary Fibrosis Foundation (PFF) and the Feldman Family to host the 4th Annual Irv Feldman Texas Hold’em and Casino Night in Deerfield, Illinois. The Irv Feldman Texas Hold’em and Casino Night was founded by the Feldman Family in 2013 in memory of their father who had succumbed to idiopathic pulmonary fibrosis (IPF). For the last 4 years, Laury, Mara, and Mitch Feldman have hosted poker and casino nights to raise money to help end pulmonary fibrosis, and this year’s event continued on following page.

This month in CHEST: Editor’s picks

By Richard S. Irwin, MD, Master FCCP

Editor in Chief, CHEST

Giants in Chest Medicine
Karlman Wasserman, MD, PhD, FCCP. By Dr. T. Kisaka, et al.

Original Research


OFEV (nintedanib) has demonstrated reproducible reductions in the annual rate of FVC decline in 3 clinical trials.

DISCOVER MORE ABOUT OFEV INSIDE.

OVER 10,000 IPF PATIENTS HAVE BEEN TREATED WITH OFEV WORLDWIDE"
featured a poker tournament, silent auction, dinner buffet, and live entertainment. This local community-based support resulted in almost $200,000 raised at the poker night to fight against pulmonary fibrosis. In collaboration with the Pulmonary Fibrosis Foundation, these proceeds will support pulmonary fibrosis patient education, disease awareness, and clinical research. We thank the Feldman Family and the Pulmonary Fibrosis Foundation for making this successful event possible.

**Allergy & Asthma Network**

Over the past 2 years, our relationship with the Allergy & Asthma Network (AAN) has grown to include collaborative disease awareness campaigns, co-branded and co-created patient education materials in asthma and COPD, and an exciting expansion of the platforms we utilize to reach patients. Partnering with the AAN has allowed us to reach new audiences and bring asthma and COPD education to local communities with opportunities, including:

- A Lifetime television segment on Access Health that focuses on asthma education;
- Co-hosted asthma Twitter chats reaching thousands of clinicians and patients; and
- “The Air We Breathe,” an Atlantic

---

**OFEV has demonstrated reproducible reductions in the annual rate of FVC decline in 3 clinical trials**

---

**Elevated Liver Enzymes**

- OFEV (nintedanib) was associated with elevations of liver enzymes (ALT, AST, ALKP, and GGT) and bilirubin. Liver enzyme increases were reversible with dose modification or interruption and not associated with clinical signs or symptoms of liver injury. The majority (94%) of patients with ALT and/or AST elevations had elevations <5 times ULN. The majority (95%) of patients with bilirubin elevations had elevations <2 times ULN.

- Conduct liver function tests prior to treatment, monthly for 3 months, and every 3 months thereafter, and as clinically indicated. Monitor for adverse reactions and consider dosage modifications, interruption, or discontinuation as necessary for liver enzyme elevations.

**Gastrointestinal Disorders**

- **Diarrhea**

  - Diarrhea was the most frequent gastrointestinal event reported in 62% versus 18% of patients treated with OFEV and placebo, respectively. Events were primarily mild to moderate intensity and occurred within the first 3 months. Diarrhea led to permanent dose reduction in 11% and discontinuation in 5% of OFEV patients versus 0 and <1% in placebo patients, respectively.

  - Dosage modifications or treatment interruptions may be necessary in patients with diarrhea. Treat diarrhea at first signs with adequate hydration and anti-diarrheal medication (e.g., loperamide), and consider treatment interruption if diarrhea continues. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists, discontinue treatment.

- **Nausea and Vomiting**

  - Nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively. Events were primarily mild to moderate intensity. Nausea and vomiting led to discontinuation of OFEV in 2% and 1% of patients, respectively.

  - If nausea or vomiting persists despite appropriate supportive care including anti-emetic therapy, consider dose reduction or treatment interruption. OFEV treatment may be resumed at full dosage or at reduced dosage, which subsequently may be increased to full dosage. If severe nausea or vomiting does not resolve, discontinue treatment.

**Embryofetal Toxicity:** OFEV can cause fetal harm when administered to a pregnant woman and patients should be advised of the potential risk to a fetus. Women should be advised to avoid becoming pregnant while receiving OFEV and to use effective contraception during treatment and at least 3 months after the last dose of OFEV. Verify pregnancy status prior to starting OFEV.
Live Summit in Chicago which focused on the relationship between air quality and respiratory health.

**COPD Foundation**

The COPD Foundation, along with Allergy & Asthma Network, have partnered with us to support our Lung Health Experience, a lung health expo touring Oklahoma City, Nashville, Chicago, and Toronto in 2017. The Lung Health Experience focuses on bringing lung health experts to the public in a comfortable, relaxed, and fun setting. The COPD Foundation and AAN have attended these events to provide the public with educational materials on lung diseases, which support the spirometry screenings performed by local respiratory therapists. We thank the Allergy & Asthma Network and the COPD Foundation for their outstanding support.

It is with these and many other partnerships that the CHEST Foundation is able to elevate its mission to champion lung health and provide local communities with an opportunity to interact with clinicians and physicians outside of a hospital setting. These experiences and collaborations are the key to strengthening the patient and clinician conversation and bridging the gap to improve patient care and outcomes.

---

**IMPORTANT SAFETY INFORMATION**

**WARNINGS AND PRECAUTIONS (CONT’D)**

**Arterial Thromboembolic Events:** Arterial thromboembolic events were reported in 2.5% of OFEV and 0.8% of placebo patients, respectively. Myocardial infarction was the most common arterial thromboembolic event, occurring in 1.5% of OFEV and 0.4% of placebo patients. Use caution when treating patients at higher cardiovascular risk including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia.

More patients had improved lung function with OFEV than with placebo in the INPULSIS® trials³

3 out of every 10 patients on OFEV showed an improvement (≤0% decline) in lung function in the INPULSIS® trials³

Less than one-third of patients on OFEV had a meaningful decline in lung function in the INPULSIS® trials³

In INPULSIS® trials, there was not a statistically significant difference in all-cause mortality for OFEV compared with placebo.⁴

**Less Than One-Third of Patients On OFEV Had a Meaningful Decline in Lung Function in the INPULSIS® Trials³⁶-⁸**

According to American Thoracic Society (ATS) guidelines, ≥10% FVC decline is an established measure of IPF disease progression and a surrogate marker in mortality⁶,⁷,⁹

More patients had improved lung function with OFEV than with placebo in the INPULSIS® trials³

3 out of every 10 patients on OFEV showed an improvement (≤0% decline) in lung function in the INPULSIS® trials³

In the INPULSIS®-1 trial, patients treated with OFEV had a greater improvement in lung function compared with placebo at 52 weeks. Please see additional Important Safety Information and brief summary for OFEV on the following pages.

---

**INPULSIS®-1³**

### More patients had improved lung function with OFEV than with placebo in the INPULSIS® trials³

<table>
<thead>
<tr>
<th>Patients with improvement</th>
<th>OFEV (n=309)</th>
<th>Placebo (n=204)</th>
</tr>
</thead>
<tbody>
<tr>
<td>67% relative increase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12% absolute difference</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**INPULSIS®-1³⁶-⁸**

<table>
<thead>
<tr>
<th>Patients with ≥10% decline in predicted FVC</th>
<th>OFEV (n=309)</th>
<th>Placebo (n=204)</th>
</tr>
</thead>
<tbody>
<tr>
<td>33% relative decrease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14% absolute difference</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS (CONT’D)**

**Arterial Thromboembolic Events:** Arterial thromboembolic events were reported in 2.5% of OFEV and 0.8% of placebo patients, respectively. Myocardial infarction was the most common arterial thromboembolic event, occurring in 1.5% of OFEV and 0.4% of placebo patients. Use caution when treating patients at higher cardiovascular risk including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia.

Please see additional Important Safety Information and brief summary for OFEV on the following pages.
Low payment for pulmonary rehab explained

BY PHIL PORTE
Executive Director, NAMDFRC

A new review of 2015 Medicare data clearly points fingers at hospitals for the historically low payment rates for pulmonary rehabilitation. To fully understand these data, everyone involved in the delivery of pulmonary rehabilitation services needs to know some of the specifics regarding Medicare’s rate setting process for hospital outpatient services. Those services are paid on the basis of a prospective payment methodology, similar to the DRG system for inpatient services. Under the outpatient system, APCs (ambulatory payment classifications) are computed with two key data sources, both provided by hospitals.

First, every claim submitted to Medicare for an outpatient service must include the hospital’s “charge”
By CMS for rate setting is the hospital cost report, submitted annually to CMS tied to the individual hospital’s fiscal year. This flow of data to CMS is ongoing because of differing fiscal years and is somewhat attributable to changes in Medicare proposed rates for the following year.

Continued on following page.
Continued from previous page

July, compared with final rates, published in early November.

The other key historical fact that needs emphasis is what happened in 2010 when CMS began reimbursing for pulmonary rehab under new HCPCS code G0424. Clearly, there were no charge data to examine, so the Agency had to do a bit of guesswork, estimating what would be a reasonable payment. CMS turned to payment information tied to codes G0237 and G0238, codes that had been used by many institutions for the previous decade for billing pulmonary rehab.

But one critical difference existed. The new code, G0424, was a 1-hour code, while G0237-38 were 15-minute codes. Over the next 2 years, even CMS cited the failure of hospitals to adjust their charges to reflect all the component services included in this new, bundled 1-hour code, compared with the unbundled 15-minute code.

The new review of CMS data bears out this problem. With approximately 1,350 institutions billing for hospital outpatient pulmonary rehab via code G0424, there is incredibly wide variance in charge data. The range is from a high of $1,981 to a low of $44, with 1,350 institutions in between. The average charge was $247, but the difference between the lowest charge and the highest charge is approximately 44-fold.

For cost report data, the spread is from $1.265 to $4 (yes, $4, based on data provided to CMS). Approximately 750 hospitals, more than half, submit data to CMS reflecting costs associated with the delivery of pulmonary rehab, per hour, at $30 or less.

There are probably several reasons why hospitals behave this way. First, there is the historical phenomenon cited by CMS that it often takes years for hospitals to adjust charges appropriately when any new HCPCS code is adopted by CMS. And, in fact, CMS cited pulmonary rehab as a glaring example of that failure by hospitals. Second, there is the cost report data, and we believe it, too, falls victim to hospital neglect. We can understand that a service such as pulmonary rehab falls so far below the radar by chargemasters, hospital administrators and others associated with information submitted to CMS that little attention is paid to accuracy of charges or administrative costs culled from the hospital cost report. And then, there is the matter of community relations. The hospitals at the very high end of the spectrum in terms of charges ($1,100 and up) are unlikely to build good community relations if they let people know of those charges. Ironically, it is fair to presume that hospitals do pay very close attention to their charges and cost report data for very high-end hospital outpatient services, micro-examining that information to ensure desirable payment rates.

So, the critical challenge to the pulmonary community is to focus on those two very specific bits of data submitted by hospitals to CMS: what a hospital identifies as the “charge” for code G0424 and is then entered on every claim submitted to G0424; and second, information correlated to the administrative aspects of pulmonary rehab that hospitals submit to CMS annually in their cost report to CMS. Until those adjustments are made, pulmonary rehab will live with unacceptable payment rates.
SPECIAL REPORT RELEASED BY FIRS
The Global Impact of Respiratory Disease – Second Edition

The Global Impact of Respiratory Disease – Second Edition was released by the Forum of International Respiratory Societies (FIRS) at the World Health Assembly May 25, 2017, in Geneva, Switzerland, calling attention to the global burden of lung disease and the benefits of prevention and clean air.

We often take our breathing and our respiratory health for granted, but respiratory diseases are a leading cause of death and disability in the world. Sixty-five million people suffer from COPD, and 3 million die of it each year, now making it the third leading cause of death worldwide. Asthma affects 334 million people in the world and is the most common chronic disease of childhood. Pneumonia kills millions of people annually and is a leading cause of death among children under 5 years old. Over 10 million people develop TB, and 1.4 million die of it each year, making it the most deadly infectious disease. Lung cancer kills 1.6 million people each year and is the most deadly cancer. Globally, at least 2 billion people are exposed to indoor toxic smoke, 1 billion inhale outdoor pollutant air, and 1 billion are exposed to tobacco smoke. Many of us, and the world, are naïve to these staggering realities.

We often take our breathing and our respiratory health for granted, but respiratory diseases are a leading cause of death and disability in the world.

The American College of Chest Physicians® (CHEST), together with FIRS, is working hard to change these realities. CHEST, and our more than 19,000 members around the world, want a better future, one that has less suffering. We want a future that enables and allows everyone to breathe freely. The 2017 Global Impact of Respiratory Disease report objectively speaks to these issues and outlines an eight-step action plan to impact these serious concerns. It highlights the importance of prevention, control, and cure of these diseases and announces that promotion of respiratory health must be a top priority for healthcare systems and decision-makers. In emphasizing that these goals are achievable, it also highlights the reality that the prevention and cure of respiratory diseases are among the most cost-effective health interventions available – a “best-buy” in the view of the World Health Organization (WHO). In addition to reducing so much suffering, investment in respiratory health will pay manifold dividends in longevity, healthy living days, and national economies.

Darcy Marciniuk, MD, FCCP, FRCPC, and Co-Chair of the Report notes, “The Global Impact of Respiratory Disease” report calls attention to the importance of respiratory health in the world. The report and these efforts are required to ensure respiratory health becomes a top priority in global decision-making. In addition to focusing attention to the importance of respiratory health in the world and ensuring it becomes a global priority, the 2017 Global Impact of Respiratory Disease report also includes practical information for our members. The report summarizes the current state of our understanding with the “Big 5”: COPD, asthma, pneumonia, lung cancer, and TB, as well as with the environment and clean air, sleep-disordered breathing, pulmonary hypertension, and pulmonary embolism. It highlights key controllable factors, such as a reduction in tobacco smoking and improvement in air quality, which includes reduction in second-hand tobacco smoke, smoke from indoor fire, and unhealthy public and workplace air. The report underlines the value of trained health-care professionals and the need for health-care systems and policies to support those trained professionals. Finally, it emphasizes the reality that investment in respiratory research is more than the hope for today – it is the promise and a genuine commitment for tomorrow.

Continued on following page
ABIM Internal Medicine Summit

BY HEATHER DETHLOFF, MA
CHEST Education and Accreditation Manager

On April 7, four members of CHEST staff and leadership, along with staff and leadership from other medical specialty societies, participated in the Internal Medicine Summit, hosted by the American Board of Internal Medicine, in Philadelphia. The meeting covered an array of topics related to certification and maintenance of certification (MOC), including the alternative assessment model announced in December 2016, quality improvement (QI) as part of MOC, and practicing medicine in an ever-changing political landscape.

The meeting began with Dr. Richard Baron, President and CEO of the ABIM, explaining how the notion of certification has changed over the years. According to Dr. Baron, the concept of lifetime certification no longer makes sense in the rapidly changing field of medicine. As part of the evolution of certification, the ABIM has moved away from “rules to follow” toward something, co-created...
with societies, that is more relevant and less burdensome. This shift includes aligning certification and MOC requirements with things physicians are already required to do by their states and institutions. Dr. Baron also stressed that in today’s cultural and political landscape, along with the prevalence of “fake news,” the need for trust in the doctor-patient relationship is increasing; trust is no longer a “given.” Therefore, in an age when credentials can be purchased online, there’s an increasing need for an external certification to build trust and boost credibility.

Dr. Marianne Green, member of the ABIM Board of Directors and the ABIM Council, gave an update on the recertification assessment options. While currently, only an every 2-year assessment option will be offered as an alternative to a 10-year higher stakes exam, the ABIM is looking to partner with societies to deliver education, based on the needs identified via the assessment. Furthermore, in addition to partnering with societies to address the identified knowledge gaps, the ABIM plans to collaborate with societies in future alternatives to both the 2-year and 10-year assessments, with the shared goal of “maintenance and support of a community of life-long learners who hold

Continued on following page
Continued from previous page

ourselves accountable to peer-defined standards.” Initially, the 2-year low-
stakes assessment will cover the breadth of the knowledge in the special-
ity/subspecialty, but the ABIM is committed to taking a more modular
approach in the future. When asked about the fee structure for the new
assessment options, Dr. Green commu-
nicated that details regarding fees
would be announced in fall 2017.

While the first part of the meet-
ing focused on MOC Part 2, the
conversation turned toward quality
improvement, or QI, later part of the
meeting. The practice improvement,
or MOC Part 4, requirement is on
hold through the end of 2018. Both
the ABIM and represented societ-
ies value the importance of quality
measures. Dr. Graham McMahon,
president and CEO of Accreditation
Council for Continuing Medical Edu-
cation (ACCME), laid the framework
for QI as being “activities that address
a quality or safety gap with interven-
tions intended to result in improve-
ment and with specific, measurable
goals. QI activities are learner-driven,
as learner engagement is a key target
of ACCME’s standards. Representatives
from the Heart Rhythm Society, the
Society of Hospital Medicine, the At-
thritis Foundation, and the American

ORENITRAM® (treprostinil)
EXTENDED-RELEASE TABLETS
Indication
Orenitram is a prostanoyl vasodilator indicated for
treatment of pulmonary arterial hypertension (PAH)
(WHO Group I) to improve exercise capacity.
The study that established effectiveness included
predominately patients with WHO functional class II-III
patients receiving anticoagulants (75%) or PAH
associated with connective tissue disease (19%).
When used as the sole vasodilator, the effect of
Orenitram on exercise is about 10% of the deficit, and
the effect, if any, on a background of another vasodilator
is probably within this.

Important Safety Information for Orenitram
Contraindications:
• Orenitram is contraindicated in patients with severe
hepatic impairment (Child-Pugh Class C)

Warnings and Precautions:
• Abrupt discontinuation or sudden large reductions in
dose of Orenitram may result in worsening of PAH
symptoms
• Orenitram inhibits platelet aggregation and increases
the risk of bleeding
• The Orenitram tablet shell does not dissolve. In
patients with duodenal ulcers, Orenitram tablets can
 lodged in a diverticulum

Drug Interactions / Specific Populations
• Concomitant administration of Orenitram with
diuretics, antihypertensive agents, or other
vasodilators increases the risk of symptomatic
hypotension
• Orenitram inhibits platelet aggregation; there is
an increased risk of bleeding, particularly among
anticoagulants
• Co administration of Orenitram and the CYP2C8
enzyme inhibitor gemfibrozil increases exposure to
treprostinil; therefore, Orenitram dosage reduction
may be necessary in these patients
• Pregnancy Category C. Animal reproductive studies
with Orenitram have shown an adverse effect on the
fetus. There are no adequate and well-controlled studies
in humans
• It is not known whether treprostinil is excreted in
human milk or absorbed systemically after ingestion.
Because many drugs are excreted in human milk,
choose Orenitram or breastfeeding
• Safety and effectiveness in patients under
18 years of age have not been established
• There is a marked increase in the systemic exposure
to treprostinil in hemiplegic patients

Adverse Reactions:
• In the 12-week placebo-controlled monotherapy
study, adverse reactions that occurred at rates at least
5% higher on Orenitram than on placebo included
headache, diarrhea, nausea, flushing, pain in jaw, pain
in extremity, hypokalemia, and abdominal discomfort
(ORENITRAM) JAN-16

TYVASO® (treprostinil)
INHALATION SOLUTION
Indication
Tyvaso is a prostanoyl vasodilator indicated for
the treatment of pulmonary arterial hypertension (PAH)
(WHO Group I) to diminish symptoms associated with
exercise. Studies establishing effectiveness included
predominately patients with WHO functional class II-IV
symptoms and etiologies of idiopathic or heritable PAH
(56%) or PAH associated with connective tissue diseases
(33%)

The effects diminish over the minimum recommended
dosing interval of 4 hours; treatment timing can be
adjusted for planned activities.

While there are long-term data on use of treprostinil
by other routes of administration, nearly all controlled
clinical experience with inhaled treprostinil has been
on a background of bosentan (an endothelin receptor
antagonist) or sildenafil (a phosphodiesterase type 5
inhibitor). The controlled clinical experience was limited
to 12 weeks in duration.

Important Safety Information for Tyvaso

Warnings and Precautions
• The efficacy of Tyvaso has not been established in
patients with significant underlying lung disease (such
as asthma or chronic obstructive pulmonary disease).
Patients with acute pulmonary infections should be
cautiously monitored to detect any worsening of
lung disease and loss of drug effect.
• Tyvaso is a pulmonary and systemic vasodilator. In
patients with low systemic arterial pressure, Tyvaso
may cause symptomatic hypotension
• Titrate slowly in patients with hepatic or renal
insufficiency, as exposure to treprostinil may be
increased in these patients
• Tyvaso inhibits platelet aggregation and increases
the risk of bleeding, particularly in patients receiving
anticoagulants
• Co administration of the cytochrome P450 (CYP) 2C8
enzyme inhibitor gemfibrozil may increase exposure to
treprostinil. Co-administration of the CYP2C8
enzyme inducer rifampin may decrease exposure to
treprostinil. Increased exposure is likely to increase
adverse events, whereas decreased exposure is likely
to reduce clinical effectiveness

Drug Interactions / Specific Populations
• The concomitant use of Tyvaso with diuretics,
antihypertensives, or other vasodilators may increase
the risk of symptomatic hypotension
• Orenitram inhibits platelet aggregation; there is
an increased risk of bleeding, particularly among
anticoagulants
• Co administration of Orenitram and the CYP2C8
enzyme inhibitor gemfibrozil increases exposure to
treprostinil; therefore, Orenitram dosage reduction
may be necessary in these patients
• Pregnancy Category C. Animal reproductive studies
with Tyvaso have shown an adverse effect on the
fetus. There are no adequate and well-controlled studies
in humans
• It is not known whether treprostinil is excreted in
human milk or absorbed systemically after ingestion.
Because many drugs are excreted in human milk,
choose Tyvaso or breastfeeding
• Safety and effectiveness in patients under
18 years of age have not been established
• There is a marked increase in the systemic exposure
to treprostinil in hemiplegic patients

Adverse Reactions:
• In the 12-week placebo-controlled monotherapy
study, adverse reactions that occurred at rates at least
5% higher on Tyvaso than on placebo included
headache, diarrhea, nausea, flushing, pain in jaw, pain
in extremity, hypokalemia, and abdominal discomfort

REMODULIN® (treprostinil)
INJECTION
Indication
Remodulin is a prostanoyl vasodilator indicated for
the treatment of pulmonary arterial hypertension (PAH)
(WHO Group I) to diminish symptoms associated with
exercise. Studies establishing effectiveness included
predominately patients with NYHA Functional Class II-IV
symptoms and etiologies of idiopathic or heritable PAH
(56%) or PAH associated with connective tissue diseases
(33%)

The effects diminish over the minimum recommended
dosing interval of 4 hours; treatment timing can be
adjusted for planned activities.

While there are long-term data on use of treprostinil
by other routes of administration, nearly all controlled
clinical experience with inhaled treprostinil has been
on a background of bosentan (an endothelin receptor
antagonist) or sildenafil (a phosphodiesterase type 5
inhibitor). The controlled clinical experience was limited
to 12 weeks in duration.

Important Safety Information for Remodulin

Warnings and Precautions
• The efficacy of Remodulin has not been established
in patients with significant underlying lung disease (such
as asthma or chronic obstructive pulmonary disease).
Patients with acute pulmonary infections should be
cautiously monitored to detect any worsening of
lung disease and loss of drug effect.
• Remodulin is a potent pulmonary and systemic
vasodilator. In patients with low systemic arterial pressure, Remodulin
may cause symptomatic hypotension
• Titrate slowly in patients with hepatic or renal
insufficiency, as exposure to treprostinil may be
increased in these patients
• Remodulin inhibits platelet aggregation and increases
the risk of bleeding, particularly in patients receiving
anticoagulants
• Co administration of the cytochrome P450 (CYP) 2C8
enzyme inhibitor gemfibrozil may increase exposure to
treprostinil. Co-administration of the CYP2C8
enzyme inducer rifampin may decrease exposure to
treprostinil. Increased exposure is likely to increase
adverse events, whereas decreased exposure is likely
to reduce clinical effectiveness

Drug Interactions / Specific Populations
• The concomitant use of Remodulin with diuretics,
antihypertensives, or other vasodilators may increase
the risk of symptomatic hypotension
• Orenitram inhibits platelet aggregation; there is
an increased risk of bleeding, particularly among
anticoagulants
• Co administration of Orenitram and the CYP2C8
enzyme inhibitor gemfibrozil increases exposure to
treprostinil; therefore, Orenitram dosage reduction
may be necessary in these patients
• Pregnancy Category C. Animal reproductive studies
with Remodulin have shown an adverse effect on the
fetus. There are no adequate and well-controlled studies
in humans
• It is not known whether treprostinil is excreted in
human milk or absorbed systemically after ingestion.
Because many drugs are excreted in human milk,
choose Remodulin or breastfeeding
• Safety and effectiveness in patients under
18 years of age have not been established
• There is a marked increase in the systemic exposure
to treprostinil in hemiplegic patients

Adverse Reactions:
• In the 12-week placebo-controlled monotherapy
study, adverse reactions that occurred at rates at least
5% higher on Remodulin than on placebo included
headache, diarrhea, nausea, flushing, pain in jaw, pain
in extremity, hypokalemia, and abdominal discomfort

More information on the Brief Summaries for Tyvaso and Remodulin on the adjacent page and
please see the Brief Summary of the Full Prescribing Information for Orenitram on the adjacent page and
the Brief Summaries for Tyvaso and Remodulin on the subsequent pages.
College of Rheumatology shared their organization’s initiatives related to QI. Apart from the focus on certification and MOC, the meeting also focused on the needs arising from a changing political world, including what is at stake with the repeal of the Affordable Care Act (ACA) and the challenges arising with the wide dissemination of questionable news and the general disregard of science. Stephen Welch, CHEST EVP/CEO, participated in a panel entitled “Practicing Medicine in a Fact-Free World.” He, along with other media professionals, discussed the challenges that physicians, patients, and physician educators encounter in a time when false facts are published as truth and information is sensationalized to attract more attention.

Since the meeting, CHEST leadership sent a letter to the ABIM leadership noting a desire to be one of the societies with whom the ABIM collaborates for both alternative assessment methods and the open-book resources selected. Additionally, CHEST expressed interest in receiving the data that are culled from the assessments, an interest aligned with CHEST’s current data analytics initiatives. CHEST will continue to collaborate with the ABIM to ensure CHEST members’ needs are represented and prioritized in future discussions.

---

**BRIEF SUMMARY**

The following is a brief summary of the full prescribing information for Orenitram® (treprostinil) Extended-Release Tablets. Please review the full prescribing information before prescribing Orenitram.

**INDICATIONS AND USAGE**

Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. The study that established effectiveness included predominantly patients with WHO functional class III symptoms and etiologies of idiopathic or heritable PAH (17%) or PAH associated with connective tissue disease (19%). When used as the sole vasodilator, the effect of Orenitram on exercise is about 10% of the deficit, and this effect, if any, on a background of another vasodilator is probably less than this.

**ADVERSE REACTIONS**

**Clinical Trials Experience:**—Because clinical trials are conducted under well-controlled conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug or may not reflect the rates observed in clinical practice. In a 12-week placebo-controlled monotherapy study (Study 1; WHO Group 1; functional class III), the most commonly reported adverse reactions occurred in patients receiving Orenitram included headache, dizziness, nausea, and flushing. Table 1 lists the adverse reactions that occurred at a rate on Orenitram at least 5% higher than on placebo. Orenitram patients in Table 1: Study 1: N=151) had access to 0.25 mg tablets at randomization. Approximately 9% of such patients experienced an adverse reaction, but only 4% discontinued therapy for an adverse reaction (compared to 3% receiving placebo). The overall discontinuation rate for any reason was 17% for active and 14% for placebo.

Orenitram was studied in a long-term, open-label extension study in which 894 patients were dosed for a mean duration of approximately 2 years. About 78% of patients continued treatment with Orenitram for at least 1 year. The mean dose was 4.2 mg/BD at one year. The adverse reactions were similar to those observed in the placebo-controlled trials. The safety of Orenitram was also evaluated in an open-label study transitioning patients from Remodulin. The safety profile during this study was similar to that observed in the three pivotal studies.

**Post-Marketing Experience:**—The following adverse reactions have been identified during post approval use of Orenitram: dizziness, dyspepsia, vomiting, myalgia, and arthralgia. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**DRUG INTERACTIONS**

**Concomitant administration of Orenitram with diuretics, antihypertensive agents, or other vasodilators increases the risk of symptomatic hypotension.**

**Anticoagulants—**—Treprostinil inhibits platelet aggregation; there is increased risk of bleeding, particularly among patients receiving anticoagulants.

**Effect of CYC286 Inhibitors—**—Co-administration of Orenitram and the CYC286 enzyme inhibitor gemfibrozil in healthy adult volunteers increases exposure to treprostinil. Reduce the starting dose of Orenitram to 0.125 mg BD and use 0.25 mg BD increments every 3 to 4 days.

**Effect of Other Drugs on Orenitram—**—Based on human pharmacokinetic studies, no dose adjustment of Orenitram is recommended when co-administered with either fluoroxazole, ritampin, sildenafil, bosentan or esomeprazole.

**Warfarin—**—A drug interaction study was carried out with Remodulin co-administered with warfarin (25 mg/day) in healthy volunteers. There was no clinically significant effect of either medication on the pharmacokinetics of treprostinil. Additional post-marketing data did not affect the pharmacokinetics or pharmacodynamics of warfarin. The pharmacokinetics of Orenitram and the international normalized ratio (INR) in healthy subjects given a single 25 mg dose of warfarin were unaffected by continuous subcutaneous infusion of treprostinil at an infusion rate of 10 mg/kg/hr.

**USE IN SPECIFIC POPULATIONS**

**Pregnancy—**—Pregnancy Category C. Animal reproductive studies with treprostinil dosed have shown an adverse effect on the fetus. There are no adequate and well-controlled studies in humans.

**Labor and Delivery—**—The effect of Orenitram on labor and delivery in humans is unknown. No treprostinil treatment-related effects on labor and delivery were seen in animal studies.

**Nursing Mothers—**—It is not known whether treprostinil is excreted in human milk or absorbed systemically after ingestion. Because many drugs are excreted in human milk, choose Orenitram or breastfeeding.

**Pediatric Use—**—Safety and effectiveness in pediatric patients have not been established.

**Geriatric Use—**—Clinical studies of Orenitram did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic or cardiac function, and of concomitant disease or other drug therapy. Patients with Hepatic Impairment—Plasma clearance of treprostinil is reduced in patients with hepatic insufficiency. Patients with hepatic insufficiency may therefore be at increased risk of dose-dependent adverse reactions because of an increase in systemic exposure. Titrate slowly in patients with hepatic insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic function. In patients with mild hepatic impairment (Child Pugh Class A) start at 0.125 mg BD with 0.25 mg BD dose increments every 3 to 4 days. Avoid use of Orenitram in patients with moderate hepatic impairment (Child Pugh Class B). Orenitram is contraindicated in patients with severe hepatic impairment (Child Pugh Class C).

**Patients with Renal Impairment—**—No dose adjustments are required in patients with renal impairment. Orenitram is not removed by dialysis.

**OVERDOSAGE**

Signs and symptoms of overdose with Orenitram during clinical trials reflect its dose-limiting pharmacokinetic effects and include severe headache, nausea, vomiting, diarrhea, and hypotension. Treat supportive.
China’s Pulmonary Crisis

BY FRASER MACKAY, MD; AND ERIC FLENNAGH, MD, FCCP

Over the past 2 years, we had the opportunity to participate in an annual cross-cultural exchange that has broadened our horizons. Xi'an, the ancient capital of China and home of the Terracotta warriors, is a sprawling megapolis similar to Los Angeles. In the southern suburb of Huxian, US trained pulmonary, neurosurgical, and critical care physicians from Cooper University Hospital and Morehouse School of Medicine partnered with physicians of Ji-Ren Teaching Hospital to deliver a Chinese Medical Association accredited continuing medical education conference. The conference agenda included a variety of pulmonary and critical care topics, highlighting sepsis, neurovascular disease, and lung

O

INDICATIONS AND USAGE

TYVASO is a pressuresensitive, vaporizable, inhaled formulation of treprostinil for long-term maintenance therapy of patients with PAH. The efficacy of TYVASO in patients with PAH has been demonstrated in two well-controlled clinical trials: TRITON (subcutaneous) and TRIUMPH (inhaled).

BRIEF SUMMARY

The following is a brief summary of the full prescribing information for TYVASO (treprostinil) Inhalation Solution. Please review the full prescribing information prior to prescribing TYVASO.

ADVERSE EVENTS

Adverse events associated with the use of TYVASO are described in Table 1: Adverse Events in ≥1% of Patients Receiving TYVASO and More Frequent than Placebo. Adverse events in patients treated with TYVASO were qualitatively similar to those observed in the 12-week, parallel-controlled trials. In a prospective, observational study comparing patients taking TYVASO (30 mg/5 mL) for 1 year or more, the most commonly reported adverse events were cough and pharyngolaryngeal pain, which occurred in 29 (25%) and 29 (25%) patients, respectively. In these trials, the safety/tolerability profile of TYVASO was similar to other inhaled long-acting prostacyclins.

Table 1: Adverse Events in ≥1% of Patients Receiving TYVASO and More Frequent than Placebo

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>TYVASO n = 345</th>
<th>Placebo n = 220</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cough</td>
<td>68 (19.8)</td>
<td>36 (16.4)</td>
</tr>
<tr>
<td>Pharyngolaryngeal pain</td>
<td>44 (12.8)</td>
<td>22 (10.0)</td>
</tr>
<tr>
<td>Nausea</td>
<td>24 (7.0)</td>
<td>11 (5.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>24 (7.0)</td>
<td>11 (5.0)</td>
</tr>
<tr>
<td>Pyrex</td>
<td>11 (3.2)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Palpitations</td>
<td>11 (3.2)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Syncope</td>
<td>3 (0.9)</td>
<td>1 (0.5)</td>
</tr>
</tbody>
</table>

*More than 3% greater than placebo

OVERDOSAGE

Severe hypotension and reflex bradycardia have been observed in pediatric patients receiving single intravenous doses of treprostinil above the recommended therapeutic range. In a 1-year clinical trial in which patients received TYVASO at a minimum dosage of 30 mg/5 mL 3 times daily, the most common adverse events were hypotension, headache, pharyngolaryngeal pain, and diarrhea.

USE IN SPECIFIC POPULATIONS

Pregnancy—Pregnancy Category B. There are no adequate and well-controlled studies with TYVASO in pregnant women. Animal reproduction studies have not been conducted with treprostinil administered by the inhalation route. However, studies in pregnant rabbits using continuous subcutaneous (SC) infusions of treprostinil indicated that risk of symptomatic hypotension was higher than the recommended human SC infusion rate resulted in an increased incidence of fetal skeletal variations associated with maternal toxicity. Also a study in pregnant rabbits administered out-10.

PHARMACOKINETICS

Treprostinil is a prostanoid that is administered either subcutaneously (SC) or intravenously (IV). In the absence of an approved pharmacokinetic model, the effect of reducing the frequency of SC injections on pharmacokinetics has been investigated. In a 12-week, placebo-controlled trial of 21 subjects, the percentage of area under the concentration-time curve (AUC) and treprostinil Cmax increased in a dose-dependent manner with an increase in the frequency of SC injections. The average AUC and Cmax for 3 weekly SC injections were 185% and 203%, respectively, of those for 1 weekly SC injection. Therefore, the frequency of SC injections should be reduced to the minimum recommended for clinical effectiveness. The pharmacokinetics of treprostinil have been studied in rats, rabbits, and dogs. In rats and dogs, treprostinil is rapidly absorbed following SC administration. In rabbits, the pharmacokinetics of treprostinil are unaffected by continuous subcutaneous (SC) infusions. The pharmacokinetics of treprostinil were unaffected by continuous subcutaneous or IV infusion of treprostinil at infusion rates higher than those observed in the clinical trials in humans. In rats and rabbits, treprostinil is extensively metabolized in the liver and is excreted in the urine. The major metabolites of treprostinil are treprostinil diolamine and treprostinil diol hemi-sulfate. The parent compound is eliminated in the urine, and the metabolism is primarily hepatic. In a 12-week, placebo-controlled trial, the safety and efficacy of treprostinil were evaluated in a population of patients with PAH and PAH associated with HIV. The study included a variety of pulmonary and critical care topics, highlighting sepsis, neurovascular disease, and lung.

OVERDOSAGE

In general, symptoms of overdose with TYVASO include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Potentially general supportive care until the symptoms of overdose have resolved.
The audience was receptive and very interested in learning. However, while we were impressed with their rapid growth and interest in incorporating western medicine into their daily practice, it was impossible to overlook the major pulmonary health-care concerns threatening their communities. Tobacco use was omnipresent, and the haze of air pollution made the sky a constant shade of grey. In both public and private spaces, powerful echoes of a once familiar America resonated, and they served to underscore the obstacles the Chinese medical community now faces in caring for their country’s pulmonary health.

An Old, Familiar Foe

The China National Tobacco Corporation (CNTC) is the largest tobacco company in the world, as well as China’s most profitable state-owned enterprise (Pratt, A, et al. WHO Report. 2017. ISBN 9789290617907 [http://www.wpro.who.int/china/publications/2017_china_tobacco_co_control_report_en_web_final.pdf?ua=1]). As such, the CNTC controls every aspect of its production and supply chain with the force of the federal government and also exerts heavy influence over regulatory policy. It controls about 98% of total domestic crop production and manages to price cigarettes just short of one American dollar per pack, yet contributes about $170 billion annually to the government (Rich, et al. Nicotine Tob Res. 2012;14[3]:258). This accounted for nearly 7% of total governmental revenue in 2015 (Pratt, 2017).

To date, nearly 44% of the world’s cigarettes are manufactured and consumed in China (Pratt 2017, Rich 2012). In 2015, more than 315 million Chinese adults were daily smokers, or about 28% of the adult population and nearly half of all men (Pratt, 2017). This is about double the proportion of US smokers (about 15.1%) and more than eight times the 3.5 million daily smokers in the United States (CDC Online Tobacco Use Report, 2016 [https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/]). However, to visit China is not only to know a love for tobacco, but also an overwhelming guest and gift culture. Gift giving and hospitality is central to the Chinese identity, from business meetings to afternoon tea. Given their economy and such rich supply, people gift cigarettes to one another at all times for nearly any occasion. Unfortunately, tobacco smoke in China is as inescapable as its health consequences.

The direct effects of smoking on China’s pulmonary health have been catastrophic. Cancers of the lung and bronchus constitute their most common malignancy across both sexes, accounting for the...
Continued from previous page

majority of the annual 4.3 million new cancer diagnoses (Chen et al., CA Cancer J Clin. 2016;66[2]:115). In Chinese men, lung cancer is the second most common cancer before the age of 60, and over the age of 75, it is the most common malignancy and also accounts for the majority of that group’s cancer mortality. Women fare only slightly better, with breast cancer being their most common malignancy, but with lung cancer remaining the most pervasive across all age groups, and, by far, the most deadly (Chen, 2016). All told, of the projected 2.8 million cancer deaths occurring in 2015 in China, 21% were directly a result of lung cancer. Likewise, COPD also threatens China. The Global Burden of Disease study conducted in 2004 demonstrated that nearly 3 million people die of COPD each year. Chinese adults over the age of 40 had an overall prevalence of COPD of 9% for the last decade, though this may be higher given COPD of 9% for the last decade, though this may be higher given COPD-related mortality in rural China (Fang, et al., Chest. 2011;139[4]:920). After 2004, the Chinese Ministry of Health affirmed that COPD was the fourth leading cause of mortality in urban areas, but third in rural ones (Fang, 2011). When investigators analyzed deaths secondary to cor pulmonale coexisting with COPD, they found COPD-related mortality increased to 179.9 for men and 141.3 for women per 100,000 persons, which is about double the COPD mortality for other countries in the Asian-Pacific region (Reilly, et al., Am J Epidemiol. 2008;167[8]:998).

Both cancer and COPD in China disproportionately affect those in rural areas and with lower socioeconomic status, with smoking being the most potent causative exposure. On average, the annual direct and indirect per-patient cost of treating COPD amounted to about $2,000, comprising about 40% of a family’s total annual income (Fang, 2011). The cost of treating malignancy is even more expensive, but the higher likelihood of death results in an additional 10% to 20% reduction of family income when a working family member dies (Pratt, 2016). Taken together, and especially since rural Chinese citizens spend close to 20% of their income on tobacco products, the pulmonary health consequences of smoking are a significant driver of both health and economic inequality.

The Air We Breathe

Air pollution comprises a second pulmonary insult to China’s health. The International Agency for Research on Cancer designated particulate matter (PM) as a class I carcinogen (Kurt O, et al., Curr Opin Pulm Med. 2016;22[2]:138). PM forms from combustion of bio-mass fuel, as well as from dust storms or construction. Once particulates are smaller than 2.5 microns (PM2.5), they cause substantial harm to the pulmonary microenvironment. Guo and colleagues demonstrated markedly increased lung cancer risks associated with spatial mapping of ozone and PM2.5 concentrations (Guo, et al., Environ Res. 2016;144:60). PM2.5 also doubles the odds of contracting COPD in non-smoking adults, conferring as much as a three-fold risk of contracting the disease in nonsmoking women (Fang, 2011).

Apart from causing pulmonary disease, studies also implicate air pollution as frequently causing exacerbations of existing disease. One study found an incremental increase in ED visits for respiratory illnesses for every 10 µg/m2 above the median PM2.5 level (Xu, et al., PLoS One. 2016;11[4]:e0153099). In 2013, 83% of Chinese lived in places where PM2.5 levels exceeded China’s own ambient air standard. In this cohort, elevated PM2.5 levels contributed directly to 300,000 premature deaths from lung cancer and COPD, with PM2.5 causing 1.2 million premature deaths overall (Liu, et al., Sci Total Environ. 2016;568:1253).

Moving Forward

The Chinese have few illusions about these pulmonary concerns, and they are making progress. The government recently introduced stricter smoking controls in Beijing and Shanghai and continues to explore ways to decrease emissions. President Xi has put forward strong initiatives to improve the health of the Chinese. However, the nation is trying to balance its national priorities in the context of a fluid, and, at times, perilous geopolitical climate. In some ways, their position is not too dissimilar from the US geopolitical and health-care situation of the 1970s. While challenging, the issue of Chinese health care should not overshadow the remarkable resources or the truly remarkable culture of their people. Friendship, cooperation, the reduction of suffering: these are ideals where all clinicians find common ground, regardless of nationality.

Dr. Mackay is Chief Fellow of Critical Care Medicine, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, New Jersey; Dr. Flenaugh is Associate Professor of Medicine, Division Chief of Pulmonary and Critical Care Medicine, Director of Advance Diagnostic and Interventional Pulmonary, Morehouse School of Medicine, Atlanta, Georgia.

Editor’s Note

This excellent, up-close Pulmonary Perspective details observations of Drs. Mackay and Flenaugh as they have participated in cross-cultural exchanges in China with realization of the many obstacles to good pulmonary health for the Chinese population, obstacles including tobacco use, COPD, and air pollution. We appreciate their bringing these observations to the forefront.

The American College of Chest Physicians, likewise concerned about pulmonary health in China, has approached the problem on a different front, working closely with partners, such as the Chinese Thoracic Society, the Chinese Association of Chest Physicians, and the Chinese Medical Doctor Association, to implement China’s first-ever fellowship program offering standardized training in PCCM for Chinese physicians. Read more at http://www.medscape.com/chester/pulmonary/article/131179/society-news/pccm- ondeveloped-pilot-subspecialty-chinese-national-health.

Nitin Puri, MD, FCCP, is the section editor of Pulmonary Perspectives.

CHEST NetWorks

Submassive PE, antibiotic resistance, advanced practice providers

Cardiovascular Medicine and Surgery

Catch 22 of Submassive Pulmonary Emboli

Venous thromboembolism (including deep vein thrombosis (DVT) and pulmonary embolism (PE)) occurs in approximately 1 per 1,000 patients (Piran S, Schulman S. Thromb J. 2016;14[5]:23) and can be fatal. Pulmonary embolus severity is classified as low risk, intermediate-risk/submassive PE, and massive PE. There is significant controversy about the management of submassive PE, which is defined as PE with right-sided heart strain (elevated troponin or B-type natriuretic peptide, right-axis deviation on ECG, or evidence of RV dysfunction on CT or echo-cardiogram), and the absence of hypotension (systolic blood pressure > 90 mm Hg). In addition to the acute manifestations of VTE, there are potential long-term complications, including postthrombotic syndrome and chronic thromboembolic pulmonary hypertension. Several trials have examined the utility of systemic thrombolysis in submassive PE (MAPPET-3 [Konstantinides, et al. N Engl J Med. 2002;347:1143], PEITHO [Meyer, et al. N Engl J Med. 2014;370:1402; Konstantinides, et al. JACC. 2017;69[12]:1536]; MOPETT [Sharifi, et al. Am J Cardiol. 2013;111:273]; and TOPCOAT [Kline, et al. J Thromb Haemost. 2014;12:459]), but all have failed to establish a mortality benefit. However, thrombolysis demonstrated decreased clinical deterioration and may mitigate the development of postthrombotic syndrome. Yet thrombolysis has been associated with increased bleeding (PEITHO: 11.5% vs 2.4% had major bleeding, and 2% vs 0.2% experienced hemorrhagic stroke). Current CHEST guidelines (Kearon, et al. Chest. 2016;149[2]:3150) recommend against the use of thrombolytics in submassive PE without hypotension. Treatment of intermediate-risk PE remains an enigma for physicians, but it is hoped that with further investigation, optimal management will be elucidated.

David J. Nagel, MD
Steering Committee Member
Olivier Axler, MD, FCCP
Vice-Chair

Continued on following page
Chest Infections

Antibiotic Resistance

One-hundred years ago, infectious diseases caused 5 of the 10 most common causes of deaths in the United States. In 2016, only one infection remained on this list (influenza/pneumonia) (MMWR Morb Mortal Wkly Rep. 2017;66:413).

How medicine has improved with antibiotics. An unfortunate and unintended consequence of widespread antibiotic use has been the progressive resistance to these drugs. It is estimated that, if current trends continue, 10 million lives a year will be at risk from resistant organisms by 2050 (O’Neill, J. (2016). https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf).

Pathogens acquire antibiotic resistance by passing genetic material to one another through plasmids, bacteriophages, or naked DNA. Once acquired, resistance manifests via a number of mechanisms under the stress imposed by antibiotics (Levy SB, et al. Nat Med. 2004;10:S122).

Among the best studied is enzymatic degradation of the antibiotic. This occurs when beta-lactamases degrade penicillin. A second mechanism alters cell transport, thereby blocking cell entry or actively ejecting the antibiotic from the cell. Finally, overexpression or alteration of the antibiotic target may render a drug ineffective at inhibiting any vital cell function.

At the pace with which resistance now develops, the medical community faces a crisis, whereby infections caused by evolving superbugs are no longer effectively controlled by the available menu of antimicrobial agents.

This challenge must be met collectively by the more prudent prescribing of antibiotics, potentially with the help of rapid diagnostics; isolation of patients potentially infected with resistant organisms; and a focus on developing newer drugs that defy known resistant mechanisms.

Marc Feinstein, MD, FCCP
Steering Committee Member

Clinical Pulmonary Medicine

COPD and sleep-disordered breathing: A missing comorbid condition

Subjective, as well as objective, sleep complaints are common in patients with COPD (Krachman S, et al. Proc Am Thorac Soc. 2008;5[4]:536), and sleeping difficulties are ranked the third most frequent complaint (behind dyspnea and fatigue) in patients with COPD (Kinsman RA, et al. Chest. 1983;83[3]:735). Also, sleep quality is poor, and patients with moderate to severe COPD may have higher-than-expected incidence of OSA (Soler X, et al. Ann Am Thorac Soc. 2015;12[8]:1219).

Unfortunately, sleep is usually not assessed during a COPD evaluation. Up to 27% of patients with COPD without hypoxia during wakefulness can experience important desaturation during sleep, so called nocturnal oxygen desaturation (NOD) (Fletcher... Continued from previous page

Continued on following page
Continued from previous page


Although identification and effective treatment of COPD comorbidities are becoming the cornerstone of COPD treatment of COPD comorbidities are going to be enough. Since there is no formal pulmonary rehabilitation, that improve dyspnea, exercise capacity, and quality of life may also positively impact sleep (Soler X, et al. COPD 2013;10(2):156). Because of the background of the staff involved, the comprehensive approach to patient assessment, and access to number of COPD subjects, pulmonary rehabilitation may be an optimal opportunity to assess sleep and identify an important comorbid condition often overlooked in patients with more advanced COPD.

Xavier Soler, MD, PhD Steering Committee Member

Interprofessional Team

Finding Home

Outside our internal medicine curriculum, there is no formal pulmonary training or post-masters fellowship in pulmonary medicine for Advanced Practice Providers (APPs). Because of this, APPs are left to their own devices to fill educational gaps. To perform at the level expected by the physicians I work for, I spent the first day with my nametag turned around. I ran into another unicorn—another APP seeking the same information, only her nametag was turned the right way. The best advice she gave was to attend the Interprofessional Network meeting. This was ground zero of the conference as far as I was concerned. There I found myself surrounded by RTs, RNs, NPs, PAs, and yes, even physicians.

Over the years, as I’ve gotten further involved with CHEST NetWorks, I have found from top to bottom CHEST striving to incorporate APPs and advance our education. From including us in the FCCP program, reducing conference pricing for APPs, and focusing this year’s conference theme around being team focused, CHEST is creating a home for APPs. Corinne Preston Young, FNP, FCCP Steering Committee Member

Critical Skills for Critical Care

A State-of-the-Art Update and Procedures for ICU Providers

August 11-13
CHEST Innovation, Simulation, and Training Center

Join an expert panel of nurse practitioners, physician assistants, and physicians for this state-of-the-art update in critical care medicine for the whole team, featuring intensive, hands-on, and simulation-based experience in high-yield ultrasound, mechanical ventilation, and airway management procedure skills.

Attend to:
- Study the latest evidence in critical care medicine from a team-based perspective.
- Get hands-on training in ultrasound imaging and interpretation, mechanical ventilator modes and settings, and airway management for the critically ill patient.
- Participate in concise, evidence-based reviews, case-based discussions, audience response, and expert debates in areas of clinical controversy.

Learn More livelearning.chestnet.org/critical-care
We’ve listened and considered all of your feedback to enhance your experience at CHEST 2017, Oct 28-Nov 1, Toronto, Canada. This year, we have changed the format of our postgraduate courses, updated our interdisciplinary sessions, and added new ways to register. Take a look at what’s new.

Postgraduate courses
New this year at CHEST 2017 is the option to attend a half-day or full-day course for a more flexible experience. There are nine, half-day sessions that include lunch, and the afternoon sessions allow people to fly in that morning to avoid an extra hotel night and missing work.

Interdisciplinary sessions
Bring your entire care team to attend programs that will address clinical issues across disciplines. Each role and perspective will be represented through session speakers, so your group can collectively experience practical, relevant updates. Sessions will combine lecture-based, case-based, and hands-on learning opportunities. Here are updated sessions:

These sessions are free but require a ticket.
Monday, October 30
• Critical Skills for ICU Directors and Their Leadership Team
• Interstitial Lung Disease: 2017 Update on Patient-Centered Management
• Lung Cancer: 2017 Update in Diagnosis and Management

Tuesday, October 31
• Challenges in ICU Management

Wednesday, November 1
• Enhancing Quality of Pulmonary Rehabilitation Programs and Integrated COPD Disease Management

Don’t forget to register for CHEST 2017!
You can now register as a group! Ten or more healthcare professionals from your team can register as a group for discounted tuition rates. Group registration is open through October 22 and will not be offered on-site. Learn more about CHEST 2017 updates and how to register at chestmeeting.chestnet.org.

Learn What’s New at CHEST Annual Meeting 2017

Skyline of Toronto, Canada

2017 Education Calendar

Live Learning Courses - Courses held at the CHEST Innovation, Simulation, and Training Center in Glenview, Illinois.

Difficult Airway Management
July 14-16

Bronchoscopy and Pleural Procedures for Pulmonary and Critical Care Medicine Fellows
July 21

Mechanical Ventilation: Advanced Critical Care Management
July 28-30

Comprehensive Pleural Procedures
August 4-5

Critical Skills for Critical Care: A State-of-the-Art Update and Procedures for ICU Providers
August 11-13

Ultrasonomography: Essentials in Critical Care
September 15-17
December 1-3

Cardiopulmonary Exercise Testing
September 22-24

Comprehensive Bronchoscopy With Endobronchial Ultrasound
September 29 - October 1

Critical Care Ultrasound: Integration Into Clinical Practice
November 10-12

> Learn More livelearning.chestnet.org

Calendar subject to change. For most current course list and more information, visit livelearning.chestnet.org.
PULMONARY and CRITICAL CARE SPECIALIST

UT Health Northeast is seeking a board certified or board eligible pulmonary and critical care specialist. This position has inpatient and outpatient responsibilities, and provides an opportunity for research as well as educational activities. Candidates must be eligible for licensure in Texas. We offer a competitive salary and comprehensive benefits provided by the State of Texas.

UT Health Northeast is a growing academic medical center in East Texas with approximately 75 clinical faculty in more than 25 medical specialties, as well as 32 research faculty. Graduate Medical Education is an integral component of UT Health Northeast and includes accredited residency programs in Family Medicine, Internal Medicine, and Occupational Medicine, with a Psychiatry residency planned to open in 2017. We have also recently partnered with MD Anderson to create the UT Health Northeast MD Anderson Cancer Center, which will open later this year.

For more information about this position, please contact:
Lindsay Waters
Physician Relations Representative
Lindsay.waters@uthct.edu
or by phone at 903-877-7266

Billings Clinic

Generous loan repayment
Join seven university-trained, board-certified Pulmonary, Critical Care and Sleep Medicine physicians. Our integrated multi-specialty physician clinic and hospital includes a Level II Trauma Center and an accredited sleep center. Practice with strong colleagues in the region’s tertiary referral center.

“America’s Best Town of 2016” – Outside Magazine

Please visit us at booth #1810 at the ATS 2017 Conference in Washington, DC!

Contact: Rochelle Woods
1-888-554-5922
physicianrecruiter@billingsclinic.com

Billings Clinic is nationally recognized for clinical excellence and is a proud member of the Mayo Clinic Care Network. Located in Billings, Montana – this friendly college community is a great place to raise a family near the majestic Rocky Mountains. Exciting outdoor recreation close to home. 300 days of sunshine!
WASHINGTON – It’s been a “relatively positive” year for heart failure research and advances in patient care, said Christopher M. O’Connor, MD, and president-elect of the Heart Failure Society of America, at the annual meeting of the American College of Cardiology.

The good news
• Empagliflozin (Jardiance) earns FDA approval for reduction in risk of cardiovascular death in type 2 diabetes patients. “This is one of the most amazing stories in heart failure,” said Dr. O’Connor, who is also professor of medicine at Duke University in Durham, N.C.

The pivotal EMPA-REG OUTCOME study showed a highly significant 33% reduction in the secondary endpoint of risk of hospitalization for heart failure, as well the decrease in cardiovascular mortality which was the primary endpoint and proved persuasive to the FDA (N Engl J Med. 2015 Nov 26;373[22]:2117-28).

“It was a remarkable development. Because of this trial, there are now a number of ongoing phase III clinical trials looking at this class of drugs in heart failure patients with and without diabetes, which makes this a very important research movement. We are now looking deeper at phenotypes and trying to get more specific with these drug therapies,” he said.

• A new and improved LVAD is developed. This fully magnetically levitated centrifugal-flow pump type of left ventricular assist device for advanced heart failure showed superior event-free survival, compared with a commercially available axial continuous-flow pump LVAD in the randomized MOMENTUM-3 trial (N Engl J Med. 2017 Feb 2,376[3]:440-50).

The novel pump was designed to overcome a significant problem with axial continuous-flow LVADs: a proclivity for pump thrombosis. The magnetically levitated centrifugal-flow pump proved a smashing success in this regard, with zero cases of pump thrombosis occurring during the 6-month study.

“This may be the first time in the history of heart failure research that the engineers have beaten the biologists in important clinical outcomes,” the cardiologist quipped.

• Omecamtiv mecarbil successfully addresses impaired contractility in heart failure with reduced ejection fraction (HFrEF). This drug, a selective cardiac myosin activator, resulted in increased duration of systole and improved stroke volume accompanied by reductions in heart rate, left ventricular end-diastolic and -systolic dimensions, and NT-proBNP in the 87-site, 13-country, phase II COSMIC-HF study (Lancet. 2016 Dec 10;388[10062]:2899-903).

“This is probably the most novel new drug mechanism out there in clinical trials,” said Dr. O’Connor, who is also CEO and executive director of the Inova Heart and Vascular Institute in Falls Church, Va.

On the basis of the highly encouraging results for the surrogate endpoints assessed in COSMIC-HF, a large phase III clinical trial known as GALACTIC is underway.

• Palliative care gets a welcome boost. Dr. O’Connor was a co-investigator in PAL-HF, a single-center study presented at the 2016 annual meeting of the Heart Failure Society of America.

“This is a very important trial of palliative care in advanced heart failure. We probably don’t have as much evidence in this space as we should,” he observed. “This was a multidisciplinary intervention in which we gave the patients a medical tool kit to alleviate pain, dyspnea, and discomfort. The tool kit included benzodiazepines, sleep medications, sublingual nitroglycerin, and morphine-like products.”

The primary outcome was change in two validated heart failure quality of life measures. Both instruments documented significant improvement compared with usual care.

“There was no decrease in mortality, which wasn’t a goal in this advanced heart failure population, and no reduction in heart failure hospitalizations, but there were significant reductions in depression and anxiety,” Dr. O’Connor said.

• Vericiguat is under study. This oral soluble cyclic guanylate cyclase stimulator missed its primary endpoint in the phase II dose-escalation SOCRATES-REDUCED trial in patients with HFrEF (JAMA. 2015 Dec 1;314[21]:2251-62), but showed an impressive improvement in quality of life. It is now the subject of the ongoing, randomized, phase III VICTORIA trial involving a planned 4,000 patients with HFrEF with the composite primary endpoint of cardiovascular death or heart failure hospitalization.

The phase II SOCRATES-PRESERVED trial also missed its primary endpoint but showed a clinically meaningful improvement in quality of life in patients with heart failure with preserved ejection fraction (HFpEF) (Eur Heart J. 2017 Mar 22. doi: 10.1093/eurheartj/ehw593). Discussions are ongoing as to whether the next step should be a confirmatory phase II study or a move straight to phase III.

The bad news
• NSAIDs linked to increased risk of heart failure. European investigators analyzed five population-based databases totaling more than 8.3 million individuals and determined that current use of any of more than two dozen NSAIDs was associated with significantly increased risk of hospital admission for heart failure. The risk appeared to be dose dependent and varied between individual agents, ranging from a 16% increased risk with naproxen to an 83% increase with ketorolac (Toradol) (BMJ. 2016 Sep 28. doi: 10.1136/bmj.4857).

• Therapeutic natriuretic peptides hit bottom. The negative results for the investigational agent ustaritide in patients with acute decompensated heart failure in the large phase III TRUE-AHF trial presented at the 2016 meeting of the American Heart Association, following upon an earlier negative study of the related drug nesiritide (Natrecor) in more than 7,100 acute heart failure patients (N Engl J Med. 2011 Jul 7; 365:32-43), probably spells the end of the line for this strategy of boosting outcomes in acute heart failure, according to Dr. O’Connor.

Moreover, Novartis has announced that the phase III RELAX-AHF-2 trial of serelaxin in 6,600 patients with acute heart failure failed to meet its primary endpoints of reduced cardiovascular deaths or reduced worsening of heart failure. The trial will be formally presented later this year.

“Ustaritide seemed to show an early improvement in heart failure events that was not sustained in-hospital, and there was absolutely no difference in mortality. The drug probably acts like a pharmacologic tourniquet, in my view. So I think this field of therapeutic natriuretic peptides is probably closed,” he said.

• ICDs don’t reduce mortality in patients with nonischemic heart failure. This was the conclusion reached in the DANISH trial, in which more than 1,100 patients with symptomatic systolic heart failure were randomized to an ICD or usual care (N Engl J Med. 2016 Sep 29;375[13]:1221-30).

“This study really shook up the field, raising the question, ‘Are we using defibrillators too frequently in this population?’ It has stimulated a lot of discussion, including within the guidelines committee,” Dr. O’Connor noted.

• Tolvaptan nixed for acute decompensated heart failure. The TACTICS-HF trial studied the use of tolvaptan (Samsca), an oral vasopressin-2 receptor antagonist, to reduce dyspnea in patients hospitalized with acute decompensated heart failure. Dr. O’Connor was a co-investigator in the study, which showed that tolvaptan was no better than placebo at 8 and 24 hours (J Am Coll Cardiol. 2017 Mar 21;69[11]:1399-406).

“For now, the routine use of vasopressin antagonists in acute heart failure is not to be encouraged, although there may still be subsets where it’s worth trying – certainly in severe hyponatremia,” the cardiologist said.

• GUIDE-IT gets lost. This was a roughly 1,000-patient randomized trial of a treatment strategy aimed at improving clinical outcomes by aggressively titrating evidence-based heart failure therapies in order to suppress natriuretic peptide biomarkers. GUIDE-IT was stopped early by the data safety monitoring board for a lack of discernible difference in outcomes, compared with usual care.

bjancin@frontlinemedcom.com
Dear Clot,

You really don’t take my breath away.

The EKOS® System quickly improves right ventricular function and pulmonary artery pressure.¹

EKOS® does much more than the current standard of PE care. It speeds time to dissolution by unwinding the clot’s fibrin structure, allowing greater lytic dispersion and accelerated absorption.² It also minimizes bleeding risk, requiring up to 4x less drug dosage than systemic delivery.³,⁴

Visit www.ekoscorp.com to learn more about the only endovascular device cleared by the FDA for the treatment of pulmonary embolism.

¹ In the Seattle II study of 150 patients with massive or submassive PE using an EKOS® and lytic combination, the mean RV/LV ratio decreased from 1.55 pre-procedure to 1.13 at 48 hours post-procedure (P<0.0001) while PA systolic pressure decreased from 51.4mmHg to 36.9mmHg (P<0.0001).

FDA CLEARED INDICATIONS: The EkoSonic® Endovascular System is indicated for the ultrasound-facilitated, controlled, and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism; the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature; and the infusion of solutions into the pulmonary arteries. Instructions for use, including warnings, precautions, potential complications, and contraindications can be found at www.ekoscorp.com. Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. THE CE MARK (CE0086) HAS BEEN AFFIXED TO THE EKOSONIC® PRODUCT WITH THE FOLLOWING INDICATIONS:

Peripheral Vasculature: The EkoSonic® Endovascular Device, consisting of the Intelligent Drug Delivery Catheter (IDDC) and the MicroSonic™ Device (MSD), is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. All therapeutic agents utilized with the EkoSonic® Endovascular System should be fully prepared and used according to the instruction for use of the specific therapeutic agent.

Pulmonary Embolism: The EKOS EkoSonic® Endovascular System is intended for the treatment of pulmonary embolism patients with ≥ 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥ 25mmHg) or echocardiographic evaluation.

EKOS and EkoSonic are registered trademarks of EKOS Corporation, a BTG International group company. “Acoustic pulse thrombolysis” is a trademark of EKOS Corporation. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd in US, EU, and certain other territories and trademarks of BTG International Ltd elsewhere. © 2016 EKOS Corporation. NA-EKO-2016-0578